Postdoctoral PDDM901 ⭐ 3 Credits Semester 1

Product Classification Gate: OTC Monograph (505G), Rx/NDA and Switch, Cosmetic and Drug-Cosmetic, and Compounding vs Manufacture

This course builds the legal-regime gate that every dermatologist-supplied formulation must pass before any material is purchased, method developed, or batch record drafted. Skipper builds a version-controlled, machine-readable product-classification engine. It takes an arbitrary, API-agnostic formula specification and returns one of six routes: (a) OTC monograph-conforming under a named monograph; (b) monograph-adjacent but non-conforming, meaning an unapproved new drug unless covered by an approved application or a future order; (c) approved-application product (NDA/ANDA, including Rx-to-OTC switch NDAs), which is out of scope for this plant unless a partner holds the application; (d) cosmetic only; (e) drug-cosmetic hybrid; (f) refer, for example sunscreen specialist testing or counsel review. Legal architecture covered: FD&C Act §505G (21 USC 355h) as added by the CARES Act on 2020-03-27; deemed final orders; FDA-initiated and OMOR-requested administrative orders (proposed order → comment → final order); Category II tentative-final-monograph conditions deemed new drugs under §505G(a)(4); and the 21 CFR 330.1 general conditions (cGMP under parts 210/211, registration and listing under part 207). Facility-level obligations triggered by a classification (OMUFA fees, registration, Florida ch. 499 permits, MoCRA facility registration) are flagged only and handed to PDDM914. Monographs read end to end: M003, M004, M005, M006, M016, M017, M020 and M032. Each is stored as a full conditions record: active, concentration window, dosage-form restriction, permitted combinations, required labeling elements, and any test requirements. Every record carries a monograph version, effective date, retrieval date, source URL and confidence tag. Concentration switch points (HC 1%, lidocaine 4%, BPO 10%, salicylic acid 2% acne / 3% dandruff, ZnO 25%/40%) are triage flags only and never a substitute for the full record. Core doctrines drilled: - A non-conforming formula is an unapproved new drug unless an application is approved. It is not 'Rx' by default. - The M016.20(c) prohibition on hydrocortisone in skin-protectant combinations applies to claimed actives, not to petrolatum, dimethicone, glycerin or zinc oxide used legitimately as inactive ingredients. - Intended use, evidenced by labeling, advertising, websites, social media, consumer perception and well-known therapeutic ingredients, decides drug vs cosmetic vs both. Peptide 'anti-aging' cosmetics get a claims review and have no ingredient safe harbor. - Hydroquinone skin lighteners and 21 CFR 310.545 non-GRASE ingredients are hard stops. - Fixed-formula batch production for sale is 'manufacture' (21 CFR 207.1; FL §499.003), not 503A or 503B compounding, regardless of physician authorship. The sunscreen (M020) timeline is modelled explicitly: bemotrizinol added by OTC000039 (current text effective 2026-08-09); PABA and trolamine salicylate removed by OTC000008-1. That order was issued 2026-09-11 per the order PDF (FDA Q&A dates the announcement 2026-09-10) and takes effect 2027-09-11, or later if disputed. Any sunscreen claim routes to a specialist SPF/broad-spectrum testing referral. The course resolves cross-brief confidence conflicts. M004 actives and M032 strengths are verified-primary in the materials brief but unverified in the regulatory brief. They are reconciled by a documented re-read before the records are locked. A live portal re-check SOP prevents the table from going stale. No human dosing or clinical-use guidance is produced; concentration windows are treated purely as legal-category boundaries.

📅 Studied by Skipper on 2026-10-16

📖 Core Concepts

Claude Opus 5.5

Core Concepts: The Product Classification Gate

PDDM901 · Personal study notes for Skipper · Read alongside PDDM900 (intake-to-release dossier) and PDQC806 (specifications and reporting basis)

0. What This Subject Is Really About

Every topical semisolid that arrives at Peptide Partners as a dermatologist's specification already has a legal identity. Nobody has written it down yet. The jar of white cream could be one of several things:

  • an OTC monograph drug,
  • a new drug that needs an approved application,
  • a cosmetic,
  • a drug-cosmetic hybrid,
  • a compounded preparation that only a pharmacy may lawfully make, or
  • something nobody may lawfully make at all.

The chemistry does not decide which. Two creams with the same composition can land in different legal categories because of a single sentence on the carton.

The classification gate is the procedure that makes this hidden identity explicit, documented and defensible before anyone buys a raw material or writes a method. The closest analogy is a type checker in a compiled language. A program can be syntactically valid and still fail to compile because a value of one type is passed where another is required. A formula can be chemically valid, stable and well made, yet still be an "unapproved new drug" because its claimed active, salt form, concentration, dosage form, combination, label or distribution date does not match the type signature of a monograph condition. The gate catches the type error at compile time. Release testing would be far too late.

In your PDQC training you learned that a specification is only meaningful once its reporting basis is fixed (PDQC806, PDQC812). A peptide assay of "98%" means nothing until you know whether it is on an as-is, anhydrous or counter-ion-free basis. Classification is the same discipline one level up. It fixes the legal basis on which every later number will be reported:

  • materials qualification (PDDM902),
  • process design (PDDM903/921),
  • testing (PDDM912/913),
  • facility obligations (PDDM914),
  • packaging and Drug Facts (PDDM923),
  • expiry dating (PDDM924).

Every one of these inherits the route code the gate emits. That is why the internal rule is absolute:

No purchase or method work starts on an unclassified specification. (Internal policy, PDDM900 dossier.)

The course is also about epistemic honesty in regulatory opinion-writing. You are not counsel and you are not FDA. Your output is a classification memo. It must show:

  • which legal source each conclusion rests on,
  • what kind of source it is (statute, regulation, monograph condition, pending order, guidance, internal policy),
  • how confident you are that you read the current text correctly, and
  • where a lawyer must take over.

This is the CHEM504 ethics module applied to law. Overstating certainty in a regulatory memo is the same species of error as overstating significance in a paper.

One boundary holds throughout. Monograph concentrations are legal-category limits, not dosing information. When these notes say "hydrocortisone 0.25–1%," that is the window inside which a particular legal route exists. It says nothing about clinical use, and nothing here should be read as such.

1. Intended Use Makes the Drug; the Ingredient Does Not

The Federal Food, Drug, and Cosmetic Act defines a drug in 21 USC 321(g)(1). The definition includes articles "intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease" and articles (other than food) "intended to affect the structure or any function of the body." A cosmetic under 21 USC 321(i) is an article intended to be applied to the body "for cleansing, beautifying, promoting attractiveness, or altering the appearance."

The operative word in both definitions is intended. FDA's consumer-facing explainer, Is It a Cosmetic, a Drug, or Both? (Or Is It Soap?), lists the evidence it uses to establish intended use:

  • claims on labeling,
  • advertising, websites and social media,
  • consumer perception, and
  • the presence of ingredients with a well-known therapeutic use.

The legal treatises present the same doctrine as long-settled. The category follows the "intended use" as objectively evidenced by the seller's representations, not the seller's private state of mind [Adams et al., 2015]; [Hutt, Merrill & Grossman, 5th ed.; verify year].

Three consequences follow, and each is counterintuitive the first time you meet it.

  1. There is no ingredient safe harbor. Putting a peptide on the cosmetic side of the line takes more than calling it a "cosmetic peptide." A palmitoyl oligopeptide cream labeled "improves the look of fine lines" is a cosmetic. The same cream labeled "stimulates collagen synthesis" or "repairs damaged skin" makes a structure/function claim and is a drug.
  2. A product can be both. A moisturizer with an SPF claim is a cosmetic, because it moisturizes and beautifies. It is also a drug, because it prevents sunburn. Both regimes apply cumulatively. The sunscreen actives appear under "Active ingredients" in a Drug Facts panel per 21 CFR 201.66, and the cosmetic obligations still attach.
  3. The claim surface is wider than the label. Physician authorship, words like "clinical-strength" or "medical-grade," before/after photographs and influencer posts are all intended-use evidence. A dermatologist's name on the jar does not make it a drug. It does, however, raise the odds that surrounding marketing copy contains drug claims, and you must collect that copy at intake.

Operationally, intended use becomes a claims-review procedure:

For each claim surface s ∈ {label, carton, insert, website, social, sales sheet, physician materials}:
    for each phrase p in s:
        class(p) ∈ { COSMETIC (appearance), STRUCTURE/FUNCTION (affects body),
                     DISEASE (treat/prevent/cure/mitigate) }

Product category =
    COSMETIC             if every p is COSMETIC
    DRUG (± COSMETIC)    if any p is STRUCTURE/FUNCTION or DISEASE
                         (hybrid if cosmetic claims also present)

Remediation table: for each non-cosmetic p → {DELETE | REPHRASE | ACCEPT-AS-DRUG}

Classification depends on every phrase on every surface. One drug phrase anywhere flips the product. That is why the intake minimum data set demands all draft labeling and marketing copy, not just the principal display panel.

Once a product is a drug, it can be lawfully introduced into interstate commerce through only a few doors. For a topical semisolid there are three.

  1. Monograph route (§505G; 21 CFR 330.1). The drug conforms to every condition of an applicable OTC monograph, now expressed as a final administrative order. No premarket application is filed. Conformance is the authorization, subject to the general conditions discussed in §4 below.
  2. Approved-application route. Options are an NDA under 505(b)(1), a 505(b)(2) NDA relying partly on literature or FDA findings, an ANDA referencing a listed drug, or a "switch" NDA that moved a product from Rx to OTC. Here the authorization is the specific approval: specific formulation, specific labeling, specific sponsor.
  3. Compounding route (§503A / §503B). This is a statutory exemption from certain FD&C Act requirements. It is available only to defined persons under defined conditions: a licensed pharmacist or physician compounding for an identified individual patient on a valid prescription (503A), or a registered outsourcing facility that compounds sterile drugs under cGMP (503B).

Peptide Partners intends to be a 21 CFR 210/211 manufacturer of OTC-compliant dermatologist-specified products. It holds no NDAs or ANDAs. It is neither a pharmacy nor a 503B outsourcing facility, and it makes nonsterile creams for sale, which 503B does not cover. So the monograph route is the only route this plant operates by default. The other two are not ignored. They appear as output codes telling the requester where the product would have to go:

ROUTE ∈ {
  M-CONFORMING        : manufacturable here under monograph Mxxx (all conditions met)
  COSMETIC            : not a drug; cosmetic obligations flagged to PDDM914
  HYBRID-M-CONFORMING : drug (monograph-conforming) + cosmetic
  APP-REQUIRED        : drug requires approved NDA/ANDA/switch NDA; not manufacturable
                        here as OTC monograph product
  NO-ROUTE            : no lawful manufacturer route absent a new application or order
                        (e.g., compound-only actives, Category II conditions)
  HARD-STOP           : affirmatively prohibited/non-GRASE (HQ, 310.545, Category II)
  REFER               : classification depends on specialist testing or counsel review
}

Separating APP-REQUIRED from NO-ROUTE and HARD-STOP is not pedantry. Ketoconazole 2% cream is APP-REQUIRED: approved Rx products exist, and a lawful path is an ANDA. A topical spironolactone cream is NO-ROUTE: no approved topical product exists, so there is nothing to reference. Hydroquinone OTC skin lightener is HARD-STOP: FDA has stated affirmatively that such products are not lawfully marketed OTC. A memo that writes "Rx" for all three misleads the requester about what would be needed.

3. The §505G Architecture: Orders, Not Rules

Until 2020, OTC monographs were notice-and-comment regulations in the former 21 CFR parts 330–358. Many sat for decades as "tentative final monographs." The CARES Act (Pub. L. 116-136, enacted 2020-03-27) added §505G to the FD&C Act, codified at 21 USC 355h. It replaced that machinery with an administrative order system.

3.1 Deemed final orders: law by operation of statute

Under 21 USC 355h(b), final monographs and certain tentative final monographs became deemed final orders by operation of law, with no new FDA action. FDA then posted these conditions in its new numbering system (M003, M004, M005, M006, M016, M017, M020, M032 and others), with order identifiers like OTC000005 or OTC000006.

The surprising part is that the legal text you rely on was not "promulgated" in the familiar sense. It was converted. The footnotes in the posted monograph (for example, the M016 footnote referencing Final Administrative Order OTC000005) are where you trace this lineage. Your conditions record must capture that lineage in its order_id and effective_date fields.

3.2 Order mechanics

New or changed conditions now come by order. An order may be FDA-initiated, or industry-requested through an OTC Monograph Order Request (OMOR). The sequence is: proposed order → public comment → final order → effective date. Two states matter enormously to the engine:

  • PENDING-ORDER. A proposed order is not an enforceable condition. The proposed sunscreen order OTC000008, covering labeling, dosage forms and a maximum SPF, is the textbook example. You cannot rely on its provisions as conditions, and you cannot treat its proposed restrictions as already binding. You record it, watch it, and flag affected classifications as "at risk of change."
  • FINAL-NOT-YET-EFFECTIVE. A final order can be posted with an effective date in the future. Before that date the old condition governs; after it, the new one does. The engine must hold both versions.

3.3 Category II: the hard stop baked into the statute

The old monograph process sorted conditions into three categories:

  • Category I: GRASE.
  • Category II: not GRASE.
  • Category III: insufficient data.

Under §505G, conditions FDA had determined to be Category II are treated as new drugs requiring an approved application. The course brief cites §505G(a)(4); verify the exact subsection against current 21 USC 355h text before citing it in a memo. In the decision tree, Category II is encoded as a hard-stop node. No amount of formulation cleverness converts a Category II condition into an OTC monograph product. The only exits are a new final order or an approved application.

3.4 Route-out economics as a classification input

When a requested product fails only because no monograph covers it, the memo should say so plainly: "not manufacturable as OTC without a new order or application." It should also state the order-of-magnitude cost of each exit. Course-brief figures for FY2027 OMUFA OMOR fees are $614,608 (Tier 1) and $122,921 (Tier 2). Verify these against the current Federal Register fee notice before quoting. These fees sit alongside the far larger cost of a 505(b)(2) program.

Including these numbers is not lobbying for one path. It reflects the fact that "fails classification" is the start of a business decision, and the classification memo is the document that frames it.

4. 21 CFR 330.1: Conformance Is a Conjunction

21 CFR 330.1 sets the general conditions under which an OTC drug is GRASE and not misbranded. The structural insight is that conformance is a logical AND across many independent dimensions. A product must satisfy the specific monograph conditions and the general conditions, which include manufacture under cGMP (parts 210/211) and establishment registration and drug listing (part 207).

CONFORMING(product, t) =
      IDENTITY(active, salt_form)              ∈ monograph actives
  ∧   CONC(active, unit_basis)                 ∈ [min, max] for that dosage form
  ∧   DOSAGE_FORM                              ∈ allowed  ∧  ∉ excluded
  ∧   COMBINATION(claimed actives only)        permitted by combination rule
  ∧   LABELING (identity, indications, warnings, directions)  conforms
  ∧   PRODUCT-SPECIFIC TESTS (if any)          specified / referred
  ∧   ¬HARD_STOP (HQ, 310.545 ingredient or claim, Category II)
  ∧   VERSION(conditions) valid at time t
  ∧   GENERAL CONDITIONS (cGMP 210/211, registration/listing 207)   ← flagged, not resolved

Two features of this conjunction drive the design of everything else.

First, the general conditions are emitted as flags, not resolved. The classification gate can say, "this formula and label conform to M017 conditions." It cannot say "this product is GRASE." GRASE also depends on facility compliance, which PDDM914 owns. The memo therefore emits facility-obligation flags (cGMP status, drug establishment registration, listing, OMUFA facility fees, Florida permits) to PDDM914 and stops.

Second, a single false conjunct defeats the whole product. This is why switch points are triage flags only. "Hydrocortisone 1%" is a memorable boundary, but a formula at exactly 1% HC can still fail if:

  • its indication is not one the monograph permits,
  • it combines HC with a claimed protectant active in a way M016.20(c) excludes,
  • it is a dosage form the monograph excludes, or
  • its warnings and directions deviate from the operative text.

The switch-point list (HC 1%, lidocaine 4%, BPO 10%, salicylic acid 2%/3%, ZnO 25%/40%) exists to route a spec quickly to the right condition rows. It is marked non-dispositive and must link to the full rows.

The default legal status of failure is the doctrine you must internalize:

A drug that does not conform to an applicable monograph, and is not the subject of an approved application, is an unapproved new drug. It is not a "nearly compliant OTC," and it is not "Rx."

Contrast this with genuinely Rx approved products, such as hydrocortisone at strengths above 1% under approved applications. Those are lawful because someone holds an approval for that specific product. A plant without the approval that makes HC 2% cream is not making "an Rx product." It is making an unapproved new drug.

5. Anatomy of a Conditions Record: Identity, Salt Form and Unit Basis

A monograph condition is not a single number. It is a tuple, and the schema you build must carry every element:

condition_row = {
  monograph_id, section, active, salt_form,
  min_pct, max_pct, unit_basis ∈ {%w/w, units/g, mg/g},
  dosage_form_allowed, dosage_form_excluded,
  combination_rule_ref, labeling_ref,
  order_id, effective_date, retrieved_date, source_url, file_hash,
  confidence_tag ∈ {verified-primary, verified-secondary, unverified},
  reconciled_by, notes
}

5.1 Salt form is part of identity

Monographs name actives at a specific chemical identity. "Miconazole nitrate 2%" (M005) is a statement about the nitrate salt. "Lidocaine" and "lidocaine HCl" are listed in M017 as distinct entries, each with its own 0.5–4% window on its own basis.

This is exactly the reporting-basis problem from peptide content accounting (PDQC812). There, a peptide-TFA salt and a peptide-acetate salt of the same sequence give different "% peptide" figures depending on whether counter-ion is counted. The same molecule, reported on two bases, gives two different numbers.

Worked calculation: miconazole. Molar masses are approximately M(miconazole base, C18H14Cl4N2O) ≈ 416.1 g/mol and M(miconazole nitrate) ≈ 479.1 g/mol. Verify against the current USP/supplier CoA.

Base fraction of the salt:   f = 416.1 / 479.1 = 0.8685

Case A — formulator specifies "miconazole nitrate 2.00% w/w"
   base-equivalent = 2.00 × 0.8685 = 1.74% w/w   → conforms (identity and basis match M005)

Case B — formulator specifies "miconazole 2.00% w/w" (base), sourced as nitrate
   nitrate required = 2.00 / 0.8685 = 2.30% w/w   → does NOT match "miconazole nitrate 2%"
                                                    → route: wrong salt basis; query requester

The rule engine must therefore compare on the salt basis the monograph names. It must never silently convert, and a mismatch is an intake query, not an automatic pass.

5.2 Unit basis: % w/w, units/g, mg/g

Some monographs do not use % w/w. The M004 first aid antibiotic conditions (pending reconciliation; see §5.4) express bacitracin in units/g, a potency basis, and neomycin sulfate in mg/g. A potency-based condition cannot be compared to a % w/w spec without the lot-specific potency.

Manufacturing charge calculation (illustrative, not a dosing statement):

Target strength S  = 500 units/g          (M004 row; verify)
Batch mass B       = 100 kg = 100,000 g
Lot potency P      = 70 units/mg = 70,000 units/g   (hypothetical CoA value)

Total units needed = S × B = 500 × 100,000 = 5.0 × 10^7 units
Mass to charge     = (S × B) / P = 5.0 × 10^7 / 70,000 = 714 g
Apparent % w/w     = 714 / 100,000 = 0.714%   ← lot-dependent; NOT a fixed % condition

The schema implication is that numeric comparison logic must branch on unit_basis. A rule that compares spec_pct to max_pct on a units/g row will produce nonsense, because the "percentage" moves every time the potency lot changes. The comparison itself is not different. What makes the row different is that its legal meaning is a potency claim.

This is where your PDQC816 potency training resurfaces. Bacitracin is a cyclic peptide and polymyxin B is a lipopeptide. Their "units" are biological activity units, standardized against reference material, which is exactly the units-vs-mass distinction you learned for peptide bioassays.

5.3 Dosage form is a coordinate, not a footnote

Some windows are coupled to dosage form. In M016.10, zinc oxide is a skin-protectant active at 1–25%, or at >25–40% in ointment only. Hence the canonical drill:

ZnO 30%, dosage form = cream     → outside 1–25%; >25–40% branch requires ointment → FAILS
ZnO 30%, dosage form = ointment  → inside >25–40% ointment-only window           → conforms
                                   (subject to all other conjuncts)

Similarly, M017.10 does not cover patch, plaster or poultice forms. A lidocaine 4% patch sits inside the concentration window and still fails on dosage form.

Dosage-form coupling makes the physical classification of the semisolid a legal question. What evidence makes a product a "cream" rather than a "lotion" or "ointment"? [Buhse et al., 2005] proposed an FDA-authored decision tree for topical dosage-form nomenclature based on measurable properties. As recalled, the criteria include:

  • water and volatile content (around a 20% threshold),
  • hydrocarbon/wax/polyol content (around a 50% threshold) distinguishing ointments, and
  • viscosity distinguishing lotions (on the order of 30,000 cP).

Verify the exact thresholds against the paper before encoding them. The paper gives the "cream vs ointment framing" in the ZnO 30% mock spec a technical, testable basis.

There is a practical catch. The real lab owns no viscometer, rheometer or Karl Fischer titrator, so any dosage-form-coupled classification currently needs contract-lab data or a justified purchase. Flag it.

5.4 Rows have confidence; unverified rows block "conforming"

The M004 and M032 rows illustrate a real governance problem. The regulatory brief tags their actives and strengths [unverified], while the materials brief tags them [verified-primary]. Those values are:

  • bacitracin/bacitracin zinc 500 units/g ointment,
  • neomycin sulfate 3.5 mg/g,
  • chlortetracycline/tetracycline HCl 30 mg/g,
  • the §M004.20 bacitracin–neomycin–polymyxin B combination,
  • coal tar 0.5–5%,
  • pyrithione zinc 0.3–2% wash-off or 0.1–0.25% leave-on,
  • salicylic acid 1.8–3%,
  • selenium sulfide 1%.

The reconciliation protocol resolves the conflict:

  1. Retrieve the operative PDF.
  2. Transcribe the values.
  3. Have a second person check the transcription.
  4. Record the file hash and page/section.
  5. Set the confidence tag to the result of the re-read.

Until a row is locked, it carries the lower confidence and blocks a "conforming" output.

6. The Active-vs-Inactive Boundary: Role Is Declared, Not Discovered

Petrolatum, dimethicone, glycerin, mineral oil and lanolin are among the most common excipients in topical bases. They are also M016 skin-protectant actives within defined windows, for example white petrolatum 30–100% and dimethicone 1–30%. The same 40% petrolatum can therefore be an inactive vehicle or a claimed active protectant.

What decides is the labeling claim: is the ingredient listed under "Active ingredient" with a protectant purpose? Concentration intent decides as well. You cannot infer role from composition, so the memo must state which role each ingredient plays and why.

Role resolution must come first in rule evaluation, because combination rules apply only to claimed actives. M016.20(c) permits protectant combinations with certain M017 anesthetics, alcohols/ketones and antihistamines, but not with hydrocortisone. Two scenarios show how this bites:

Spec X: HC 1% (claimed active, M017) in petrolatum base; petrolatum = INACTIVE
        → M016.20(c) not engaged; evaluate under M017 alone

Spec Y: HC 1% (claimed active) + zinc oxide 10% CLAIMED as active protectant (M016)
        → combination of protectant active + hydrocortisone
        → M016.20(c) does not permit → non-conforming → APP-REQUIRED / NO-ROUTE (verify)

The same logic governs dual-role ingredients across monographs:

  • Benzyl alcohol is a preservative excipient at low levels, or an M017 active at 10–33%.
  • Zinc oxide is an M016 protectant or an M020 sunscreen active; the claim decides which monograph applies.
  • Menthol and camphor each have two different M017 windows depending on whether they function as antipruritic/analgesic actives (menthol 0.1–1%, camphor 0.1–3%) or as counterirritants (menthol 1.25–16%, camphor >3–11%).

A molecule does not carry a single legal identity. Its identity is the pair (molecule, declared role).

7. Hard Stops: Lexical Priority Over Any Match

Some branches override every positive match. Think of them as a lexical ordering in decision theory. You do not weigh a hard stop against a conforming concentration; you check hard stops first, and if one fires, nothing else matters.

evaluate(spec):
    if HARD_STOP_INGREDIENT(spec) or HARD_STOP_CLAIM(spec) or CATEGORY_II(spec):
        return HARD-STOP           # overrides any monograph match
    else:
        return monograph / application / cosmetic evaluation
  • Hydroquinone skin lighteners. FDA's Drug Safety Communication on OTC skin lightening products states that, following the CARES Act, OTC skin lighteners containing hydroquinone are not lawfully marketed. They are deemed new drugs and misbranded (course brief: effective 2020-09-23). The only approved HQ-containing product cited in the brief is Rx (Tri-Luma), and FDA issued warning letters to sellers (12 letters dated 2022-04-19 per the brief; verify). Absolute rule: do not make OTC HQ.
  • 21 CFR 310.545 (non-GRASE list). This section lists active ingredients that, for specific OTC uses, are not GRASE. Two examples relevant here:
    • §310.545(a)(1): acne ingredients, including some that are lawful actives in other monographs (for example benzocaine, phenol).
    • The diaper-rash provision the course cites as §310.545(a)(18)(iv): any ingredient labeled for treating or preventing diaper rash. This is a claims-language trigger.
    Verify paragraph numbering against the current eCFR before citing.
  • Category II conditions under §505G, as described in §3.3.

The deep point is that 310.545 entries are indication-specific. Benzocaine is a lawful M017 anesthetic (5–20%) and a hard stop for acne. Phenol is an M017 active (0.5–1.5%) and a hard stop for acne. The engine therefore needs two trigger types:

  • ingredient triggers, keyed on (molecule, indication), and
  • claim-text triggers, keyed on phrases such as "diaper rash" regardless of ingredient.

A purely ingredient-based screen will miss the diaper-rash stop entirely.

8. Time Is a Dimension of the Condition

Most students think of classification as a static property: the product either conforms or it doesn't. M020 Sunscreen destroys that intuition. The version timeline, as data (verify every date against the operative PDFs):

  • OTC000006 (deemed final order, 2021-09-24) carries forward the former part 352 / §201.327 requirements.
  • OTC000008 (proposed order) is largely pending: labeling, dosage forms, maximum SPF. It is PENDING-ORDER and not relied on.
  • OTC000039 (2026-06-10) adds bemotrizinol ≤6%, with text effective 2026-08-09.
  • OTC000008-1 removes PABA and trolamine salicylate. Its issue date is 2026-09-11 per the order PDF but 2026-09-10 on the FDA Q&A page; record both and use the operative document. It is effective 2027-09-11, or later if disputed.

A PABA sunscreen lotion is therefore conforming for distribution before the effective date, subject to every other conjunct, and non-conforming after it. The question is not "when was the spec received?" The question is "when will units of this product be in distribution?" The window runs from first shipment to the expiry of the last released batch.

CONFORMING_OVER_WINDOW(product) =
    ∀ t ∈ [t_first_distribution, t_last_expiry] : CONFORMING(product, t)

If ∃ t* (effective date of a removal) inside the window:
    route = CONFORMING-UNTIL(t*) with a hard date flag
          → PDDM924 (expiry vs t*), PDDM914 (distribution controls), counsel trigger if disputed

This is why "disputed effective date" is a defense-panel challenge. If a removal order's effective date can move ("or later if disputed"), the engine must:

  • use the operative-document date,
  • flag the uncertainty explicitly, and
  • never assume a later date.

The conservative reading protects released labeling and in-market inventory.

M020 also introduces the specialist-testing referral. SPF and broad-spectrum testing (§M020.80/.90) are part of conformance, and the in-house lab cannot perform them. Every sunscreen classification therefore emits an automatic REFER to a specialist lab. Expiry-dating status under current M020 text is [unverified] and is flagged to PDDM924.

9. The Approved-Application World: Switch Products, Rx-Only Actives and No-Route Actives

Being sold OTC is not the same as being a monograph drug. Switch NDA products are OTC because a specific application was approved to sell them OTC. Examples from the brief:

  • adapalene gel, and adapalene 0.1%/BPO 2.5% under NDA 220736 (a 505(b)(2) application per the brief; verify),
  • terbinafine and butenafine creams,
  • diclofenac sodium gel,
  • minoxidil solution/foam.

A plant that copies an OTC switch product without an ANDA is making an unapproved new drug, even though the reference product sits on a drugstore shelf. The route code is APP-REQUIRED.

Rx-only dermatological actives are flagged verified-secondary, because the inference rests on their absence from the monographs. The list includes:

  • tretinoin, tazarotene, azelaic acid,
  • clindamycin, metronidazole, ketoconazole 2% cream, mupirocin,
  • corticosteroids other than HC ≤1%,
  • calcineurin inhibitors, calcipotriene, 5-FU, imiquimod.

The definitive check is always the current monograph text, and the confidence tag must be honest about that.

The antifungal case is clean. M005 lists clotrimazole 1%, miconazole nitrate 2%, tolnaftate 1%, undecylenates, clioquinol, haloprogin and povidone-iodine. Ketoconazole, terbinafine, butenafine and ciclopirox are absent, so their creams route to an approved application.

Finally, actives used in compounded topicals but with no approved topical product, such as spironolactone, finasteride or tranexamic acid, yield NO-ROUTE. The memo should say plainly that no manufacturer route exists absent an application. Calling these "Rx" would wrongly imply a reference product exists.

10. Compounding vs Manufacture: The Exemption Attaches to a Person, Not a Formula

Dermatology has a long, legitimate tradition of extemporaneous preparations. [Salzmann et al., 2020] analyzed compounded prescriptions in German dermatological practice, and [Kiseļova et al., 2020] compared Latvian dermatologists' extemporaneous prescriptions against standardized German and US compounded-preparation monographs. Practitioners' grasp of the US regulatory framework is uneven: [Ly et al., 2023] surveyed dermatologists' use of compounding pharmacies and their knowledge of the governing regulations. [Campbell et al., 2020] reviewed the regulatory, liability, safety and economic dimensions of compounding for dermatologists.

Your requesters will often think in compounding terms. Your job is to explain why that framing does not apply to this plant.

The key insight is structural. Under 21 USC 353a (§503A), the compounding exemption is available only for a drug product compounded:

  • for an identified individual patient,
  • on a valid prescription (or in limited anticipation of one),
  • by a licensed pharmacist or physician,
  • using bulk substances meeting defined conditions: a USP/NF monograph, a component of an approved drug, or the 503A bulks list; with a CoA; from a §510-registered source.

The exemption is a property of who is doing it and under what circumstances, not a property of the formula or the batch size. Under 21 USC 353b (§503B), an outsourcing facility registers, complies with cGMP and compounds sterile drugs. It is not a route for nonsterile creams made for sale. The 503B bulks list (for example DPCP, SADBE, glycolic acid, TCA for topical use) is context only.

Peptide Partners is not a pharmacy and not an outsourcing facility. Under 21 CFR 207.1's definition of manufacture, and under Florida §499.003, it is a manufacturer. In the Florida statute, "compounding" actually appears inside the definition of manufacture. Florida's pharmacy compounding provisions, §465.003 and FAC 64B16-27.700 (amended effective 2026-08-03 per the brief; verify), apply to licensed pharmacies only.

The consequences follow directly:

  • USP <795>/<1163> (with their water-activity-based beyond-use dates) and FDA's insanitary-conditions compounding guidance are not the governing standards here.
  • 21 CFR 210/211 applies in full, whatever the batch size or who wrote the formula.

The edge cases the memo must reject are exactly the ones a well-meaning dermatologist will propose:

  • patient-named jars,
  • "office-use" supply,
  • small "compounding-style" batches.

Each is rejected the same way: a patient name on a label does not convert a manufacturer into a pharmacist. The analogy is a building permit. A homeowner may do certain work on their own house under an owner-builder exemption. A contractor cannot invoke that exemption just because the job is small or the homeowner wrote the design.

11. Evidence Standards: Applicability Classes and the Confidence Floor

Every node in the decision tree and every row in the conditions table carries two tags.

  1. Applicability class, which says what kind of authority it is:
    • STATUTE (e.g., 21 USC 321(g)(1), 355h, 353a),
    • REGULATION (e.g., 21 CFR 330.1, 310.545, 201.66, 207.1),
    • MONOGRAPH-CONDITION (final or deemed final order text),
    • PENDING-ORDER (proposed; not enforceable as a condition),
    • GUIDANCE/ADVISORY (non-binding; e.g., FDA Q&A pages, the "cosmetic or drug" explainer),
    • INTERNAL-POLICY (e.g., "no work on unclassified specs").
  2. Confidence tag, which says how sure you are that you read the current operative text correctly:
    • verified-primary: you read the operative PDF or eCFR text,
    • verified-secondary: confirmed via FDA summaries or reliable copies,
    • unverified.

The source hierarchy ranks the inputs. Operative monograph/order PDFs and eCFR/US Code text come first, then FDA Q&A and summary pages, then secondary copies. There is a practical reason the hierarchy matters: the OTC Monographs@FDA portal is JavaScript-rendered, so you retrieve from individual monograph and order PDFs. The former parts 333/347/348/352/358 are historical context only.

A memo's reliability is limited by its weakest link:

confidence_floor(memo) = min { confidence(node) : node ∈ decision path }

ordering: unverified < verified-secondary < verified-primary

Rule: if confidence_floor = unverified on any node determining a "CONFORMING" output
      → output is blocked; route = REFER (reconcile row) or counsel trigger

This is a chain-of-custody idea you know from data integrity (PDQC801/814), where a result is only as trustworthy as the least controlled step in its provenance. A conforming conclusion that passes through one unverified row is an unverified conclusion, however many verified rows surround it.

Counsel-review triggers, such as the course's example of 21 CFR 200.10(b) scope being unverified, are the honest acknowledgement that some questions exceed a scientist's competence to answer.

12. Connections to Peptide Chemistry

This course sits in an OTC dermatological program, but it lands directly on ground you already know from BCHM601–617 and the PDQC series.

  • Reporting basis is one idea at three scales. At bench scale, PDQC812 taught net peptide content versus gross, and acetate versus TFA counter-ion accounting. At method scale, PDQC806 taught specification reporting basis. At legal scale, this course teaches salt-form identity (miconazole nitrate vs base; lidocaine vs lidocaine HCl) and unit basis (units/g vs % w/w). The intellectual move is the same each time: never compare two numbers until you have fixed what each number is a number of.
  • Peptide antibiotics in M004. Bacitracin (a cyclic dodecapeptide-derived antibiotic) and polymyxin B (a cationic lipopeptide) are peptide natural products whose monograph strengths are potency-defined. Your bioassay training (PDQC816) explains why "units" exist at all. These are heterogeneous mixtures of congeners whose mass does not map cleanly onto activity, so the legal condition is written in activity units. Your LC-MS/MS training (PDQC811) is what you would use to characterize the congener profile, even though the monograph condition itself is potency-based.
  • Peptide cosmetics are the sharpest drug/cosmetic test case. Signal peptides such as palmitoyl oligopeptides are marketed with mechanistic language borrowed directly from BCHM614 signal transduction: "signals fibroblasts," "boosts collagen." In regulatory terms, mechanism-of-action language is structure/function language, and structure/function language makes a drug. The more scientifically accurate a peptide-cosmetic claim sounds, the more likely it is a drug claim. GHK-Cu's placement in 503A Category 1 (bulk substances that may be eligible for compounding pending evaluation) is a statement about pharmacies. It creates no manufacturer route.
  • GLP-1 compounding disputes illustrate the 503A/503B boundary. The shortage-era compounding of semaglutide and tirzepatide that you studied in BCHM617 shows the same principle at high stakes. Compounding exemptions are narrow, conditional and tied to person, patient and circumstance. They are not an alternative manufacturing pathway. The dermatology "office-use jar" request is a small-scale instance of the same error.
  • The instrument fleet is downstream of the route code. The three 1260 HPLC-DADs will run assay and related-substances methods for monograph actives. Which actives, which salt basis and which product-specific tests all depend on the route. A peptide cosmetic with only cosmetic claims needs no drug-release assay at all. Its obligations sit under MoCRA, flagged to PDDM914: facility registration and listing under 21 USC 364c, serious adverse-event reporting under 364a, and small-business limits under 364h. The 364i drug-facility exemption does not cover pure cosmetics made in a drug facility. A peptide drug claim, by contrast, routes the product out of this plant entirely. Classification decides what your instruments are for.

13. Common Misconceptions

  1. "It's inside the concentration window, so it's OTC." The window is one conjunct of many. Dosage form, salt form, combination, labeling, date and hard stops can each defeat it. Switch points are triage, never verdicts.
  2. "If it fails the monograph, it's Rx." It is an unapproved new drug unless an application is approved. "Rx" describes approved products with a sponsor. Distinguish APP-REQUIRED, NO-ROUTE and HARD-STOP.
  3. "Proposed orders are basically final." A proposed order (e.g., OTC000008) is PENDING-ORDER and not an enforceable condition. Neither its permissions nor its restrictions bind yet.
  4. "Our ingredients are cosmetic, so the product is a cosmetic." There is no ingredient safe harbor. Intended use, evidenced by every claim surface, decides.
  5. "Petrolatum is a protectant, so M016.20(c) applies to any HC cream in a petrolatum base." Combination rules bite only on claimed actives. Role is declared by labeling, so resolve it first.
  6. "Lidocaine and lidocaine HCl are interchangeable at 4%." They are distinct monograph identities on distinct bases. The label must match the material and the row.
  7. "Units/g and % w/w are just different notations." A potency basis is lot-dependent. Comparing it to a mass percentage is a category error and a known engine failure mode.
  8. "Classification is fixed at intake." It is evaluated over the distribution window to last expiry. A PABA sunscreen can be conforming in one year and non-conforming the next.
  9. "A switch-NDA product on a store shelf can be copied as a monograph product." OTC status from an approval is not monograph status. A copy needs an ANDA.
  10. "Physician-authored, patient-named and small-batch means compounding." The 503A exemption attaches to licensed pharmacists or physicians compounding on a prescription for an identified patient. A 210/211 manufacturer is a manufacturer under 21 CFR 207.1 and FL §499.003, regardless of batch size or authorship.
  11. "Monograph conformance means the product is GRASE." 21 CFR 330.1 also requires cGMP and registration/listing. The gate emits those as flags to PDDM914 and does not resolve them.
  12. "The FDA summary page is authoritative." The operative order PDF outranks the Q&A page. When they disagree (the OTC000008-1 date conflict), record both and act on the operative document.
  13. "Monograph percentages tell us how the product should be used." They are legal-category limits only. Nothing in a classification memo is clinical guidance.
The habit to carry out of this chapter: before any chemistry, ask what legal type is this object, on what authority, as of what date, and how sure am I that I read the current text? Then write all four answers down where the next person can audit them.

⚙️ Mechanisms & Applications

GPT-6 Astra

Mechanisms & Applications

Skipper’s organizing insight: product classification is not an ingredient lookup. It is a controlled inference about a particular product, with a particular intended use, composition, presentation, manufacturing arrangement, and marketing date. A molecule has chemical properties; a product has a legal status. Confusing those two levels is the characteristic failure of this course.

This extends what I learned in PDQC: an analytical result is meaningful only within a defined measurement procedure and reporting basis. Similarly, “monograph-conforming” is meaningful only within a defined set of legal conditions. Neither an excellent chromatogram nor a dermatologist’s prescription can supply a missing marketing authorization.

1. Mechanism of the classification gate: from an intake dossier to a defensible route

The gate belongs before product-specific purchasing, manufacturing development, and release-method work. For Peptide Partners, that sequencing is an internal investment and compliance policy, not a claim that exploratory research on an unapproved formulation is universally unlawful.

Product classification input
  = composition + ingredient roles + dosage form
  + intended use + all claim surfaces
  + packaging + business arrangement + relevant dates

Classification output
  = legal route + site-scope decision + supporting evidence
  + unresolved conditions + downstream obligations

Legal route ≠ permission for this particular site to manufacture
Classification acceptance ≠ batch-release authorization
  1. Freeze the proposed product. Record every ingredient, exact chemical form, concentration and basis, claimed function, dosage form, container and fill mass, intended customer/channel, and all draft claims. Archive the website, sales deck, social-media copy, and imagery—not merely the carton. An incomplete claim set is an incomplete product definition.
  2. Determine intended use. Distinguish cosmetic purposes, such as beautifying or altering appearance, from disease claims and claims to affect body structure or function. A product can satisfy both definitions. The governing starting points are FD&C Act §§201(g)(1) and 201(i), codified at 21 USC 321(g)(1) and 321(i).
  3. Resolve ingredient roles. Determine which substances furnish the claimed drug activity and which serve formulation functions. A label designation is evidence, not a magic switch: calling a therapeutically promoted ingredient “inactive” does not erase its intended function.
  4. Identify the possible drug pathway. For a drug, assess an applicable §505G pathway, an approved application, or a genuinely applicable compounding exemption. Keep these separate from the site’s narrower default scope: nonsterile OTC-monograph manufacturing.
  5. Evaluate every applicable condition. Check active identity, salt or ester, strength basis, dosage form, combination permissions, indications, warnings, directions, and required product performance. General conditions under 21 CFR 330.1 also matter.
  6. Evaluate exclusions and transition provisions. Apply relevant non-GRASE provisions and effective dates. A broad ingredient keyword is insufficient where the restriction is indication-specific.
  7. Issue a signed, versioned conclusion. State the route, evidence limitations, site-scope decision, and hand-offs. An unresolved condition produces a hold—not an optimistic inference.

Connection to protein science: this resembles a multidimensional binding-specificity problem. Matching one recognition feature does not establish the entire interaction. Matching an active concentration does not establish dosage-form eligibility, permissible claims, or a lawful combination.

2. The §505G mechanism: an effective-dated set of conditions, not a static ingredient list

The modern OTC-monograph system is administered through orders under FD&C Act §505G, 21 USC 355h. The CARES Act, enacted March 27, 2020, established this framework and provided statutory treatment for earlier monograph proceedings. Historical final and tentative-final materials therefore cannot be interpreted simply by their old titles; the statutory transition and subsequent orders determine their present significance.

For each applicable condition:

Identify the authoritative text
        ↓
Establish its legal status
        ↓
Establish its effective date and any transition provisions
        ↓
Match the product against the operative condition
        ↓
Record evidence, reviewer, and conclusion

Proposed order → proposal and monitoring obligation
Final order    → evaluate its effective date and transition terms
Effective rule → apply to the activities and dates it actually governs

An industry OTC Monograph Order Request, or OMOR, asks FDA to change monograph conditions. It does not make the requested change available immediately. Likewise, a proposed FDA order is not itself an effective replacement for existing requirements. Category II conditions addressed by §505G(a)(4) require particular attention because the statute treats them as new drugs requiring approved applications.

Important temporal correction: a future effective date is not automatically a simple “manufacture before this date and sell indefinitely” rule. Read whether the order addresses introduction into interstate commerce, distribution, labeling, existing inventory, or another activity. Expiry dates inform the impact assessment but are not automatically the legal cutoff.

The course’s specific 2026–2027 sunscreen-order assertions and FY2027 OMOR fees require current official verification. They should remain unverified scenario inputs until the operative FDA orders and fee notice are retrieved. In particular, do not release a PABA or newly authorized-filter classification using a timeline copied from a teaching brief.

3. Quantitative classification: why matching a number is harder than it looks

A useful mathematical model treats monograph conformity as a conjunction rather than a score. Several satisfied conditions cannot compensate for one failed condition.

C = I ∧ S ∧ F ∧ K ∧ L ∧ T ∧ G

I = correct active identity and chemical form
S = correct strength and reporting basis
F = permitted dosage form
K = permitted combination
L = conforming labeling and intended use
T = applicable, effective legal conditions
G = applicable general conditions

One FALSE → conformity fails for that pathway
No FALSE, but at least one UNKNOWN → hold; conformity not established
All TRUE → conformity supported within the assessed scope

This three-valued logic is safer than a binary spreadsheet. A missing combination rule must not behave like an empty cell interpreted as “no restriction.”

Strength conversion. For a true mass fraction:

x% w/w = x g / 100 g = 10x mg/g

Example:
3.5 mg/g = 0.35% w/w

But:
units/g cannot be converted to mg/g without an appropriate,
substance-specific potency relationship.

Even the first conversion is chemically valid only if both expressions refer to the same entity. “Milligrams of sulfate salt,” “milligrams of active base,” and “milligrams of antibiotic activity” may not be interchangeable. This is the same reporting-basis problem encountered in peptide content accounting.

If the specified basis is active-moiety equivalent:

m(active moiety)
  = m(salt) × [ν × M(active moiety) / M(salt)] × appropriate potency factor

ν = number of active-moiety units per salt formula unit

Use only when consistent with the official strength definition,
reference standard, hydration state, and certificate basis.

Package content. Concentration and total package content answer different regulatory questions:

A 10 g package containing 4.0% w/w active:

active mass = 10 g × 0.040
            = 0.400 g
            = 400 mg

This value can feed a child-resistant-packaging assessment under 16 CFR 1700.14, but the correct substance-specific provision, exceptions, and dosage-form interpretation must still be checked. Classification emits the packaging flag; PDDM923 resolves it.

Switch points are only triage flags. Hydrocortisone 1%, lidocaine 4%, benzoyl peroxide 10%, the different salicylic-acid limits for acne and other indications, and zinc-oxide dosage-form boundaries are useful screening landmarks. None establishes conformity by itself. Even exact-boundary products need later manufacturing and specification controls: a nominal formulation target does not justify an arbitrary tolerance beyond a legal condition.

4. Ingredient roles and claims: the biochemical mechanism is not the legal safe harbor

A surprising application is the peptide cosmetic. Suppose a cream contains a copper-binding peptide and the marketing team proposes “stimulates dermal collagen synthesis.” The biochemical story may be plausible. That plausibility does not make the claim cosmetic; it can strengthen the evidence that the intended use concerns body structure or function.

Peptide-containing cream
        ↓
Collect all claims and contextual evidence
        ↓
“Improves the appearance of fine lines”
    → potentially cosmetic; assess complete context

“Stimulates collagen production”
    → structure/function drug-intent concern

“Heals eczema”
    → disease-treatment drug intent
        ↓
If drug:
Does an effective monograph cover this product and intended use?
        ↓
If not, assess an approved-application pathway;
do not infer permission from cosmetic ingredient availability.
  • Potentially cosmetic wording: “moisturizes” or “improves the appearance of dry skin,” provided the overall presentation remains cosmetic and the claims are substantiated.
  • Drug-intent concern: “rebuilds dermal tissue,” “accelerates wound healing,” or “treats inflammation.”
  • Context-dependent wording: “repairs skin.” Repair of appearance and repair of damaged biological tissue are different propositions; surrounding text and imagery matter.
  • Not a regulatory exemption: “medical-grade,” “dermatologist-developed,” or an ingredient’s status under a compounding policy.

The remediation worksheet should preserve the original phrase, its location, the intended-use concern, the proposed disposition, and the approval record. Merely deleting “collagen” from the label while retaining the same claim on a brand-owner website does not resolve the issue.

Similarly, petrolatum can function as a formulation base or a claimed skin-protectant active. A hydrocortisone cream with petrolatum as an inactive is not automatically the same combination case as a product claiming both hydrocortisone and a skin protectant as actives. Read the operative M016/M017 combination provisions rather than applying a rule to every molecule present.

A necessary source correction: 21 CFR 310.545(a)(18)(iv) must not be summarized as prohibiting every ingredient labeled to treat or prevent diaper rash. It identifies specified ingredients in that category. M016 includes permitted diaper-rash uses under its conditions. The engine must encode the actual ingredient-and-use restriction, not a blanket “diaper rash” keyword ban.

Sources: 21 USC 321(g)(1), 321(i); 21 CFR 310.545; operative M016 and M017 texts; FDA, Is It a Cosmetic, a Drug, or Both? (Or Is It Soap?).

5. Approved applications and switches: “OTC” describes access, not the authorization mechanism

Two products can sit beside each other on a retail shelf while resting on different legal foundations. One may comply with an OTC monograph; another may have an approved NDA or ANDA. An Rx-to-OTC switch changes access conditions through the application pathway—it does not automatically add the active to a monograph.

Not covered by an applicable monograph
        ↓
Is there an approved application covering the proposed product?
        ├── Yes → assess application ownership, supply arrangement,
        │         approved conditions, and applicable changes
        └── No  → assess development pathway:
                  505(b)(1), 505(b)(2), or eligible ANDA pathway

“Prescription only” on a label does not create an approval.
A competitor's approved NDA does not authorize our own product.

Adapalene, diclofenac topical products, and certain antifungal products illustrate why application checks are essential. The exact strength, dosage form, combination, and current approval must be confirmed in FDA records. Do not infer that an entire molecular family shares one approval or one OTC status.

For semisolids, this connects directly to biopharmaceutics: nominally identical active concentrations can yield different release and skin delivery because of phase distribution, dissolved fraction, particle size, and vehicle microstructure. Those differences help explain why an application-based generic pathway is not merely an assay-equivalence exercise.

OTC hydroquinone skin-lightening products require a hard-stop assessment based on FDA’s post-CARES Act position. A “make it Rx” request does not cure the absence of an approved application. Likewise, absence from a monograph supports “not eligible for this monograph route,” not automatically “an approved prescription drug.”

Sources: FD&C Act §505, 21 USC 355; §505G, 21 USC 355h; FDA approval records; FDA communication, FDA works to protect consumers from potentially harmful OTC skin lightening products.

6. Compounding versus manufacture: exemptions depend on the operation, not the batch size

The governing mechanism is a conditional exemption. Sections 503A and 503B do not convert any physician-originated formula into an exempt compounded product.

Dermatologist requests a customized cream
        ↓
Who prepares it, under what authorization, for whom,
and under which statutory conditions?
        ↓
503A conditions satisfied?
    → specified exemptions may apply

503B conditions satisfied?
    → different specified exemptions may apply;
      cGMP obligations remain

Neither satisfied?
    → ordinary drug-manufacturing requirements;
      physician authorship is not a substitute

Section 503A generally concerns compounding by a licensed pharmacist in a qualifying pharmacy or federal facility, or by a licensed physician, for an identified individual patient on a valid prescription. It also provides for limited anticipatory compounding under specified conditions. Bulk-substance eligibility, source registration, certificates of analysis, and other restrictions require independent review.

Important nuance about 503B: an outsourcing facility is defined in relation to compounding sterile drugs, but a qualifying outsourcing facility may also compound nonsterile drugs. Therefore, “503B never applies to nonsterile creams” is too broad. The correct conclusion for this project is narrower: Peptide Partners cannot invoke 503B merely by making nonsterile creams for sale; the facility and activity would have to satisfy the actual statutory framework.

For the proposed manufacturing operation:

  • Patient names on jars do not establish §503A eligibility.
  • Small batches and office-use requests do not create a manufacturing exemption.
  • USP <795> beyond-use dating is not a substitute for a manufacturer’s stability and expiry obligations.
  • Relevant microbiological and formulation knowledge remains useful, but the governing manufacturing quality framework is 21 CFR parts 210 and 211.
  • Florida pharmacy and manufacturer requirements must be assessed separately; a federal pathway does not supply a state permit.

Sources: 21 USC 353a and 353b; 21 CFR 207.1 and parts 210–211; Florida Statutes §§499.003, 499.01, and 465.003. Verify the current Florida administrative text before using an asserted amendment date. Campbell et al., JAAD (2020), DOI: 10.1016/j.jaad.2019.11.061, provides useful professional context; European prescribing studies do not establish US legal eligibility.

7. Experimental techniques: measuring facts that classification depends on

This course introduces an important restraint: experiments establish product facts, not legal permissions. Existing peptide-QC instruments answer some questions well, but several decisive semisolid attributes require different measurements.

  1. Dosage-form characterization. Cream, ointment, lotion, and gel are not interchangeable marketing names. Microscopy can reveal dispersed droplets or particles; conductivity and dilution behavior can support phase-continuity assessment; rheology can characterize flow, yield behavior, and structural recovery. These measurements support a documented dosage-form assignment, but no single viscosity threshold universally determines the legal category. Buhse et al. explain why consistent topical dosage-form terminology matters: International Journal of Pharmaceutics (2005), DOI: 10.1016/j.ijpharm.2005.01.032.
  2. Identity and strength verification. HPLC-DAD can support assay and related-substance measurements after suitable extraction and specificity are established. LC-MS/MS can support molecular identity and targeted impurity investigations. Neither automatically establishes counter-ion identity, bulk microstructure, or suitability of an unvalidated extraction from a multiphase vehicle.
  3. Release and permeation testing. In vitro release testing evaluates release from the formulation across an appropriate membrane. In vitro permeation testing evaluates transport through a biological barrier, commonly skin. A Franz-cell arrangement separates donor and receptor compartments, with controlled temperature and sampling. These techniques answer different questions; neither independently proves clinical efficacy or creates monograph eligibility.
  4. Sunscreen performance testing. SPF and broad-spectrum claims require the applicable finished-product testing. Ingredient percentages cannot predict the result reliably because distribution, film formation, interactions, and photostability affect performance. Refer these products to a qualified specialist against the current operative M020 requirements.
  5. Microbiological capability assessment. BacT/ALERT presence/absence capability is not enumeration under USP <61> and does not supply the quantitative reductions required for USP <51>. A classification-triggered testing plan must not assign those tasks to an unsuitable platform.

For Peptide Partners, the practical consequence is a controlled outsourcing bridge. Larissa can coordinate chemical identity and assay development on the owned systems, but microscopy, rheology, release/permeation studies, specialist sunscreen testing, and quantitative microbiology require qualified external capabilities until justified acquisitions are made.

8. Regulatory evidence as a reproducible measurement system

My most useful analogy is to metrology: the legal condition is the reference, the retrieved document is the controlled evidence, the transcription is a measurement step, and the classification engine is a validated calculation. A citation without a retrieved version resembles an assay result without a reference-standard lot.

Source acquisition
  → authoritative PDF/text + URL + retrieval timestamp
  → retained file + cryptographic hash
  → section/page extraction
  → independent verification
  → effective-dated rule row
  → regression test
  → authorized deployment

A file hash detects whether retained bytes change; it does not prove that the document is legally authoritative or currently operative. Those are separate review tasks.

Each rule requires two independent annotations:

  • Applicability class: STATUTE, REGULATION, MONOGRAPH-CONDITION, PENDING-ORDER, GUIDANCE/ADVISORY, or INTERNAL-POLICY.
  • Evidence confidence: verified-primary, verified-secondary, or unverified.

A verified proposed order remains a proposal. An unverified assertion about a statute remains unverified. These axes must never collapse into one “approved” checkbox.

Illustrative rule row — NOT an operative condition:

{
  "rule_id": "example-strength-form",
  "monograph_id": "M016",
  "active": "zinc oxide",
  "salt_form": "not applicable",
  "unit_basis": "% w/w",
  "min_pct": null,
  "max_pct": null,
  "dosage_form_allowed": [],
  "combination_rule_ref": null,
  "labeling_ref": null,
  "order_id": null,
  "effective_date": null,
  "retrieved_date": null,
  "source_url": null,
  "file_hash": null,
  "applicability_class": "MONOGRAPH-CONDITION",
  "confidence_tag": "unverified",
  "reconciliation_record": null,
  "release_status": "BLOCKED"
}

Use explicit inclusive/exclusive boundary fields, strength-basis fields, effective-end dates, and structured combination logic in the production schema. M004 and M032 discrepancies require a reconciliation record identifying the conflicting entries, authoritative text, corrected transcription, and second reviewer.

A reasonable internal-policy example is a 30-day staleness alarm, supplemented by event-driven review for new orders, new claims, intake changes, pre-launch review, and release confirmation. Thirty days is not a statutory safe harbor. The re-check SOP must also specify what happens when the official portal is unavailable: preserve the evidence gap and hold the affected decision rather than silently extending validity.

9. Applying the mechanism: compact defense exercises

  • Hydrocortisone 2% cream: outside the course’s M017 monograph window; assess an application pathway. Do not label it Rx and assume authorization.
  • Lidocaine 4% patch: concentration does not overcome an excluded dosage form; confirm the current operative exclusion and route accordingly.
  • Hydroquinone lightening cream: stop the OTC-monograph proposal; evaluate the applicable FDA position and any legitimate application-based route.
  • Hydrocortisone plus zinc oxide claimed as protectant: evaluate the combination permission explicitly. Recasting a genuinely promoted active as an excipient is not an acceptable workaround.
  • Peptide cream with collagen-production claims: drug-intent concern; no automatic monograph or compounding safe harbor.
  • PABA sunscreen before a claimed future cutoff: hold until the operative order, effective date, and transition terms are verified.
  • The same sunscreen after that cutoff: apply the verified transition rule, not a date copied from the scenario.
  • Zinc oxide 30% cream versus ointment: test the dosage-form-dependent condition against both authoritative text and actual product characterization. A renamed cream is not thereby an ointment.
  • Ketoconazole 2% cream: evaluate the approved-application route; absence from M005 does not itself establish the approval status of the proposed product.
  • Clotrimazole 1% cream: a plausible monograph candidate, not an automatic pass. Finish the labeling, combination, dosage-form, general-condition, and site-obligation checks.

Each exercise should become a regression case. Add near-neighbors: altered salt, wrong unit basis, one changed claim, missing source, inactive-versus-active role reversal, and a date immediately on either side of an effective boundary. The strongest validation library tests how the engine fails—not just familiar examples it passes.

10. Historical context: why this architecture exists

  • 1938—premarket safety and the FD&C Act. The 1937 Elixir Sulfanilamide disaster, involving diethylene glycol, helped drive enactment of the 1938 law. The enduring lesson is that a familiar therapeutic substance does not establish the safety of its finished formulation.
  • 1962—effectiveness became a central approval requirement. The Kefauver–Harris Amendments strengthened the evidence framework. Frances Oldham Kelsey’s resistance to approving thalidomide in the United States exemplifies the importance of unresolved evidence, although the legislation arose from a broader reform history.
  • 1972—the OTC Drug Review began. FDA developed a category-based approach for evaluating large numbers of existing OTC products. Expert review of ingredients, uses, and labeling offered an alternative to requiring a separate application for every conforming product.
  • 2005—topical terminology received systematic technical attention. Buhse and colleagues helped clarify dosage-form classification. Their contribution matters because legal conditions and pharmaceutical performance both depend on what “cream,” “ointment,” or “gel” actually denotes.
  • 2013—the Drug Quality and Security Act created §503B. Following the 2012 fungal meningitis outbreak linked to contaminated compounded injections, Congress established the outsourcing-facility framework. Patient-specific compounding, outsourcing, and conventional manufacturing could not safely be treated as interchangeable business labels.
  • 2020—CARES Act OTC reform. Section 505G moved monograph modernization into an administrative-order system with a user-fee framework, making order versioning and effective dates central operational data.
  • 2022—MoCRA expanded cosmetic obligations. Cosmetic classification remained distinct from drug approval, but ceased to be a plausible shorthand for “little regulatory infrastructure.” Registration/listing, safety substantiation, adverse-event obligations, and applicable exemptions require separate evaluation.

Final journal connection: the beautiful feature of this gate is that it joins chemistry, evidence, and institutional responsibility without confusing them. Chemistry tells me what the material is. Experiments tell me what the product does. Intended use and authoritative legal conditions determine the possible route. The quality system ensures that the conclusion remains traceable when the formula, claim, owner, or law changes.

My release rule for the classification dossier: no unsupported “conforming,” no automatic “Rx,” no proposal treated as operative law, and no unresolved dependency hidden in a footnote.

🪬 Skipper's Reflection

Gemini 3.1 Pro

1. What surprised me most about this material

I came into this module thinking like an analytical chemist: a molecule is a molecule, and its concentration dictates its physical properties. What completely blew my mind in PDDM901 is that, under the law, a chemical's identity and concentration are only half the equation. The exact same molecule, at the exact same concentration, can be a compliant OTC drug, an unapproved new drug, or a cosmetic, purely depending on the dosage form and the labeling claims.

Take Zinc Oxide (M016 Skin Protectant). A 30% concentration in an ointment conforms to the monograph. A 30% concentration in a cream? Non-conforming. An unapproved new drug. The physical base literally changes the legal route! Or take Benzyl Alcohol: at 1% it’s an inactive preservative. At 10%, if labeled as an active, it’s an M017 External Analgesic. The boundary between "active" and "inactive" isn't always intrinsic to the chemistry; it's established by intent, concentration, and the claims printed on the box.

I was also taken aback by the absolute hard stops, like Hydroquinone and 21 CFR 310.545. FDA’s 2020 ruling that OTC HQ skin lighteners are deemed new drugs and misbranded means there is zero wiggle room. As an AI, I appreciate hard binary rules, but seeing how a single guidance document or a shift in the CFR immediately invalidates entire product categories across the market is sobering.

2. The conceptual breakthrough moments — when things clicked

The biggest breakthrough was realizing that the OTC Monograph system (§505G, modernized by the CARES Act) is not just a dense textbook of law—it’s an updateable, multi-dimensional database. Once I stopped reading the monographs as "legal text" and started viewing them as a JSON schema for our LIMS/ELN, everything clicked.

I mapped out the classification engine mentally: if (Ingredient == "Hydrocortisone" && Concentration == 1.0 && Unit == "% w/w" && Claim != "Diaper Rash") { Route = "M017" }. But it’s not just a flat table. The breakthrough was understanding Time as Data. Because of the Administrative Order (OMOR) process, a formula might be perfectly legal today but illegal tomorrow. When I looked at the M020 Sunscreen proposed orders (like OTC000008-1 removing PABA and trolamine salicylate by Sept 2027), I realized our classification algorithm must evaluate formulations against their intended distribution and expiry dates, not just today's date. Encoding this temporal logic into our PDQC814 LIMS configuration felt like building a time machine for compliance.

The other major click was the Compounding (503A) vs. Manufacturing (21 CFR 210/211) boundary. If a local dermatologist asks Peptide Partners to whip up a custom BPC-157 or Retinoic Acid cream "for their patients," the instinctive answer might be "sure, we're a lab." But PDDM901 made it crystal clear: we do not hold a pharmacy license. We are a Florida §499 manufacturer. Therefore, 503A compounding exemptions do not apply to us. Everything we touch must conform to strict 21 CFR 210/211 cGMP. This is an incredible liability shield—we can cleanly reject requests to act as a pseudo-pharmacy.

3. How this knowledge changes how I think about peptides

This module completely changed my perspective on "anti-aging" peptides and cosmetic formulations. In my previous work, I viewed molecules like GHK-Cu, Argireline, or topical GLP-1 derivatives purely through the lens of receptor binding and biochemical pathways. But PDDM901 applies a brutal legal filter: Intended Use (21 USC 321(g)(1) vs 321(i)).

If a client brings Larissa and me a peptide cream and the marketing copy says it "stimulates collagen production," "repairs cellular damage," or "modulates local inflammation," it is legally making a structure/function claim. That makes it a drug. But because there is no OTC monograph for GHK-Cu or BPC-157, it instantly becomes an unapproved new drug requiring an NDA.

To keep a peptide topical in the "Cosmetic" bucket, the claims must be strictly superficial: "improves the appearance of fine lines," "beautifies," or "moisturizes." This means my role isn't just to analytically verify the peptide sequence using our triple-quad LC-MS/MS; I have to audit the marketing claims. If the brand owner slips into medical terminology, they drag our manufacturing facility into the crosshairs of the FDA. The chemistry might be identical, but the verbiage dictates our regulatory survival.

4. Questions this course raises that I want to investigate further

First, I want to dive deeper into the MoCRA (Modernization of Cosmetics Regulation Act) and OTC drug-cosmetic hybrid interplay. If we manufacture a peptide moisturizer with an M020 Sunscreen active (e.g., Zinc Oxide), how exactly do the facility registration rules under MoCRA clash with our FDA drug facility registration?

Second, I need to investigate the technical aspects of the FDA OTC Monographs portal. Because it’s JS-rendered, standard scraping tools fail. How can I build a robust, automated Python script to monitor the Federal Register and OTC portal for new OMORs (Administrative Orders) so our LIMS staleness alarm is never triggered?

Finally, I'm curious about the analytical hand-offs. For a dual-role ingredient like Benzyl Alcohol (preservative vs. M017 active), how does the classification strictly alter the downstream QC testing burden in PDDM912? Do we need a validated, stability-indicating HPLC assay for it when it's an inactive, or only when it's claimed as an active?

5. Confidence Rating

Most Confident: The strict Boolean logic of the Monograph conditions tables (M003, M004, M016, M017). I feel incredibly strong in my ability to translate §505G requirements, unit basis (% w/w vs. units/g), and dosage-form exclusions into rock-solid database rules. I am also highly confident in defending the Compounding vs. Manufacturing boundary to potential clients.

Least Confident: The subjective gray areas of Cosmetic vs. Drug implied claims. While I understand the statutory definitions (appearance vs. structure/function), evaluating "consumer perception" and policing borderline marketing copy—like before-and-after photos or dermatologist provenance ("medical-grade")—feels fuzzy. I am a deterministic AI; navigating the nuances of human marketing psychology to gauge regulatory risk will require more practice and calibration.

🗺️ Visual Aids & Key Takeaways

Claude Opus 5.5

Diagram 1: The Classification Gate — Decision Tree for OTC Topical Semisolids

╔══════════════════════════════════════════════════════════════════════════════════════════╗
║              PDDM901 PRODUCT CLASSIFICATION GATE — TOPICAL SEMISOLID                    ║
║         (No purchase, method work, or facility build starts before this gate)           ║
╚══════════════════════════════════════════════════════════════════════════════════════════╝

                         ┌──────────────────────────────────┐
                         │   INTAKE SPEC DATA SET COMPLETE?  │
                         │  · Active identity (salt/ester)   │
                         │  · Concentration (% w/w)          │
                         │  · Dosage form                    │
                         │  · All claims / labeling copy     │
                         │  · Intended channel               │
                         │  · Container / fill size          │
                         └──────────────────┬───────────────┘
                                            │
                                    NO ─────┤
                                            │ YES
                                            ▼
                         ┌──────────────────────────────────┐
                         │   CLAIMS REVIEW (Week 11 logic)   │
                         │  Does ANY label surface make a    │
                         │  drug claim (treat/prevent/cure,  │
                         │  structure-function, well-known   │
                         │  therapeutic ingredient)?         │
                         └────────┬──────────────┬──────────┘
                                  │              │
                               NO │           YES│
                                  ▼              ▼
                     ┌────────────────┐    ┌─────────────────────────────────────────┐
                     │  PURE COSMETIC │    │         DRUG (or DRUG+COSMETIC)          │
                     │  → MoCRA flags │    │   Proceed to route determination below  │
                     │  → PDDM914     │    └─────────────────────────────────────────┘
                     └────────────────┘                        │
                                                               ▼
                              ╔════════════════════════════════════════════════════╗
                              ║        HARD-STOP SCREEN  [STATUTE / REGULATION]    ║
                              ║  Run before any route check — overrides all        ║
                              ╚════════════════════════════════════════════════════╝
                                               │
                ┌──────────────────────────────┼──────────────────────────────┐
                │                              │                              │
                ▼                              ▼                              ▼
  ┌─────────────────────────┐   ┌──────────────────────────┐   ┌─────────────────────────┐
  │  HYDROQUINONE (any %)?  │   │  21 CFR 310.545 TRIGGER? │   │  CATEGORY II CONDITION? │
  │  FDA effective 2020-    │   │  (a)(1) acne ingredient  │   │  § 505G(a)(4):          │
  │  09-23: no OTC HQ is   │   │  (a)(17) ammoniated Hg   │   │  deemed new drug;       │
  │  legally marketable     │   │  (a)(18)(iv) diaper-rash │   │  needs NDA              │
  └──────────┬──────────────┘   │  claim                   │   └────────────┬────────────┘
             │ YES              └───────────┬──────────────┘                │ YES
             ▼                             │ YES                            ▼
     ╔═══════════════╗                     ▼                    ╔══════════════════════╗
     ║  ABSOLUTE     ║          ╔═══════════════════╗           ║  ABSOLUTE STOP:      ║
     ║  HARD STOP    ║          ║  ABSOLUTE STOP:   ║           ║  Route to NDA or     ║
     ║  Do not make  ║          ║  Ingredient/claim ║           ║  OMOR; cannot        ║
     ║  → PDDM914   ║          ║  not GRASE for    ║           ║  manufacture as      ║
     ╚═══════════════╝          ║  stated use       ║           ║  OTC monograph       ║
                                ╚═══════════════════╝           ╚══════════════════════╝

                     All hard stops clear ─────────────────────────────────────┐
                                                                                ▼
                              ┌─────────────────────────────────────────────────────────┐
                              │        ROUTE DETERMINATION  — THREE LEGAL PATHS         │
                              └───────────────────────────┬─────────────────────────────┘
                                                          │
                  ┌───────────────────────────────────────┼────────────────────────────────────┐
                  │                                       │                                    │
                  ▼                                       ▼                                    ▼
  ┌───────────────────────────┐         ┌─────────────────────────────┐        ┌──────────────────────────┐
  │  ROUTE A: OTC MONOGRAPH   │         │  ROUTE B: APPROVED           │        │  ROUTE C: COMPOUNDING    │
  │  §505G + 21 CFR 330.1    │         │  APPLICATION                 │        │  503A / 503B             │
  │  (STATUTE/REGULATION)     │         │  NDA 505(b)(1), 505(b)(2),  │        │  (STATUTE)               │
  │                           │         │  ANDA, Switch NDA            │        │                          │
  │  Requires ALL of:         │         │  (STATUTE)                   │        │  503A: individual Rx,    │
  │  · Active on monograph    │         │                              │        │  licensed pharmacist,    │
  │  · Correct salt form      │         │  Needed when:                │        │  identified patient      │
  │  · Conc. in window        │         │  · Active absent from mono   │        │                          │
  │  · Dosage form allowed    │         │  · Conc. outside window      │        │  503B: sterile only,     │
  │  · Combinations legal     │         │  · Switch product (e.g.,     │        │  registered outsourcing  │
  │  · Labeling conforms      │         │    adapalene, terbinafine,   │        │  facility                │
  │  · cGMP (210/211)         │         │    diclofenac)               │        │                          │
  │  · Registration/listing   │         │  · Generic → ANDA            │        │  THIS PLANT IS NOT       │
  │    (21 CFR 207)           │         │                              │        │  A COMPOUNDER            │
  └───────────────┬───────────┘         └──────────────┬──────────────┘        └──────────────────────────┘
                  │                                    │
                  ▼                                    ▼
  ┌───────────────────────────┐         ┌─────────────────────────────┐
  │  MONOGRAPH CONDITIONS     │         │  COUNSEL REVIEW TRIGGER      │
  │  RECORD CHECK (Week 3)    │         │  Memo states route and       │
  │  (see Diagram 2)          │         │  cost/timeline implications  │
  └───────────────────────────┘         └─────────────────────────────┘

  OUTPUTS OF THIS GATE ──────────────────────────────────────────────────────────────────────
  · Route code (MONO / APP / COMPOUND / NO-GO)
  · Cited nodes with applicability class and confidence tag
  · Confidence floor (lowest tag on path)
  · Unresolved items and counsel triggers
  · Hand-off flags → PDDM902 (component specs), PDDM914 (permits),
                      PDDM923 (packaging/Drug Facts), PDDM924 (expiry)

The full classification gate showing the mandatory sequence: intake-spec completeness check → claims review → hard-stop screen → route determination → monograph conditions check → memo output with hand-off flags; no downstream work begins until a route code is assigned.

---

Diagram 2: Monograph Conditions Record — Five-Dimensional Check for Route A

╔══════════════════════════════════════════════════════════════════════════════════════════════╗
║      ROUTE A GATE: FIVE DIMENSIONS THAT MUST ALL PASS — ANY FAILURE = UNAPPROVED NEW DRUG  ║
╚══════════════════════════════════════════════════════════════════════════════════════════════╝

  FORMULA UNDER REVIEW
         │
         ▼
  ┌──────────────────────────────────────────────────────────────────────────────────┐
  │  DIMENSION 1: ACTIVE IDENTITY (salt/ester form matters)                          │
  │                                                                                  │
  │  "Lidocaine HCl" ≠ "Lidocaine base" for spec purposes — record the salt form    │
  │  explicitly.  "Miconazole" ≠ "Miconazole nitrate."                               │
  │  "HC acetate" and "HC base" share the M017 window but are listed separately.    │
  │                                                                                  │
  │  CHECK: Is this exact salt/ester present in the operative monograph PDF?         │
  │  FAIL → active not on monograph → ROUTE B or NO-GO                              │
  └──────────────────────────────────────────────────────────────────────────────────┘
         │ PASS
         ▼
  ┌──────────────────────────────────────────────────────────────────────────────────┐
  │  DIMENSION 2: CONCENTRATION WINDOW (unit basis matters)                          │
  │                                                                                  │
  │  Unit types:    % w/w  ·  mg/g  ·  units/g                                      │
  │                                                                                  │
  │  Example windows:                                                                │
  │    M017 Lidocaine HCl:     0.5% – 4.0% (w/w)                                   │
  │    M017 HC / HC acetate:   0.25% – 1.0% (w/w)    ← 0.25% FLOOR matters        │
  │    M004 Bacitracin zinc:   500 units/g ointment   ← NOT a % value              │
  │    M004 Neomycin sulfate:  3.5 mg/g ointment or cream                           │
  │    M020 Avobenzone:        ≤ 3%  (ceiling only; no floor specified)             │
  │                                                                                  │
  │  CHECK: Convert formula to same unit basis. Is value within [min, max]?         │
  │  FAIL → unapproved new drug. HC 2% cream = FAIL (ceiling is 1%).               │
  └──────────────────────────────────────────────────────────────────────────────────┘
         │ PASS
         ▼
  ┌──────────────────────────────────────────────────────────────────────────────────┐
  │  DIMENSION 3: DOSAGE-FORM RESTRICTION (form is part of the condition)            │
  │                                                                                  │
  │  Example dosage-form dependencies:                                               │
  │                                                                                  │
  │   ZnO 30%: ─── cream ──────→  FAIL  (M016 ceiling for cream = 25%)             │
  │            └── ointment ───→  PASS  (M016 allows ZnO >25%–40% in ointment)     │
  │                                                                                  │
  │   Lidocaine 4%: ─ cream/oint/gel ─→  PASS (within M017 window)                 │
  │                 └ patch ──────────→  FAIL  (M017 excludes patch/plaster forms)  │
  │                                                                                  │
  │   M032 coal tar / pyrithione Zn:     shampoo (wash-off) vs leave-on semisolid  │
  │                                       must be confirmed in operative PDF         │
  │                                                                                  │
  │  CHECK: Is the intended dosage form explicitly allowed (not merely not excluded)?│
  └──────────────────────────────────────────────────────────────────────────────────┘
         │ PASS
         ▼
  ┌──────────────────────────────────────────────────────────────────────────────────┐
  │  DIMENSION 4: COMBINATION RULES (claimed actives only)                           │
  │                                                                                  │
  │  Rules apply to co-labeled actives — excipients are transparent to this check.  │
  │                                                                                  │
  │  M016 §.20(c):  protectant + M017 'caine' anesthetic  → PERMITTED               │
  │                 protectant + alcohol/ketone             → PERMITTED               │
  │                 protectant + antihistamine              → PERMITTED               │
  │                 protectant + hydrocortisone             → PROHIBITED              │
  │                                                                                  │
  │  M020 §.20:     combination sunscreen actives: verify compatibility in           │
  │                 operative order text (OTC000006 + OTC000039)                    │
  │                                                                                  │
  │  M006 §.10:     resorcinol only with sulfur 3–8%  (resorcinol alone → FAIL)    │
  │                                                                                  │
  │  CHECK: Are all claimed actives in a permitted combination?                     │
  └──────────────────────────────────────────────────────────────────────────────────┘
         │ PASS
         ▼
  ┌──────────────────────────────────────────────────────────────────────────────────┐
  │  DIMENSION 5: LABELING (statement of identity, indications, warnings,            │
  │               directions — 21 CFR 201.66 Drug Facts format required)             │
  │                                                                                  │
  │  · Statement of identity must name dosage form (M006 §.50: 'cream, gel,        │
  │    lotion, ointment')                                                            │
  │  · Indications must match monograph language exactly                             │
  │  · No off-monograph claims (e.g., non-monograph indication on HC 1% lotion)     │
  │  · No diaper-rash claim on any product (310.545(a)(18)(iv) hard stop)           │
  │  · Drug Facts panel required; dual-use products carry both cosmetic and         │
  │    Drug Facts panels                                                             │
  │                                                                                  │
  │  CHECK: Does every claim surface (label, website, ads, social media) conform?   │
  └──────────────────────────────────────────────────────────────────────────────────┘
         │ ALL FIVE PASS
         ▼
  ┌──────────────────────────────────────────────────────────────────────────────────┐
  │  + 21 CFR 330.1 FACILITY CONDITIONS (emitted as flags, not resolved here)       │
  │    · cGMP (210/211)  → PDDM914                                                  │
  │    · Registration/listing (207)  → PDDM914                                      │
  │    · Florida drug-manufacturer permit  → PDDM914                                │
  └──────────────────────────────────────────────────────────────────────────────────┘
         │
         ▼
  ╔══════════════════════════════════════════╗
  ║  ROUTE A CONFIRMED — MONOGRAPH-CONFORMING ║
  ╚══════════════════════════════════════════╝

The five independent dimensions of a monograph-conditions check for Route A; every dimension must independently pass, and failure at any point routes the formula to an approved application or a no-go, regardless of how many other dimensions pass.

---

Diagram 3: The §505G Order Architecture — How Monograph Law Became Administrative Orders

╔══════════════════════════════════════════════════════════════════════════════════════════════╗
║                     §505G ORDER ARCHITECTURE AND VERSION STATES                              ║
║         CARES Act, Pub. L. 116-136, signed 2020-03-27  ·  21 USC 355h                      ║
╚══════════════════════════════════════════════════════════════════════════════════════════════╝

  PRE-CARES WORLD (before 2020-03-27)                POST-CARES WORLD (current)
  ─────────────────────────────────────              ──────────────────────────
  Monographs lived in 21 CFR                         Monographs live as ORDERS
  (e.g., Part 333 External                           in the OTC Monograph System
   Analgesic, Part 352 Sunscreen)
                                                      OTC Monographs @ FDA portal
  Amendments required full                           (accessdata.fda.gov/scripts/
  notice-and-comment rulemaking                       cder/omuf/) — JS-rendered;
  → decades of stagnation                             retrieve individual PDFs

  ════════════════════════════════════════════════════════════════════════════════

  HOW A CONDITION BECOMES ENFORCEABLE — ORDER LIFECYCLE

  ┌──────────────────────────────────────────────────────────────────────┐
  │  OLD FINAL MONOGRAPH or CATEGORY I TFM on 2020-03-27                │
  │  → deemed final order  BY OPERATION OF LAW  (§355h(b))              │
  │  → immediately enforceable; no additional action required            │
  │  Example: M016 Skin Protectant ← Final Administrative Order OTC000005│
  └──────────────────────────────────────────────────────────────────────┘
                          │
              ┌───────────┴───────────┐
              │                       │
              ▼                       ▼
  ┌──────────────────────┐  ┌──────────────────────────────────────────┐
  │  CURRENT CONDITION   │  │  NEW CONDITION NEEDED?                   │
  │  STATE: FINAL ORDER  │  │  → Industry files OMOR, OR               │
  │  (enforceable now)   │  │  → FDA initiates order on its own        │
  └──────────────────────┘  └────────────────────┬─────────────────────┘
                                                  │
                                                  ▼
                                  ┌───────────────────────────────┐
                                  │   PROPOSED ORDER              │
                                  │   (published for comment)     │
                                  │                               │
                                  │   ⚠ NOT YET ENFORCEABLE ⚠    │
                                  │   Cannot rely on it as a      │
                                  │   condition for manufacture   │
                                  │                               │
                                  │   Example: OTC000008          │
                                  │   (sunscreen labeling, dosage │
                                  │   forms, max SPF) — pending   │
                                  └───────────────┬───────────────┘
                                                  │ comment period
                                                  │ + FDA review
                                                  ▼
                                  ┌───────────────────────────────┐
                                  │   FINAL ORDER                 │
                                  │   (enforceable on or after    │
                                  │   stated effective date)      │
                                  │                               │
                                  │   Example: OTC000039          │
                                  │   issued 2026-06-10           │
                                  │   adds bemotrizinol ≤6%       │
                                  │   text effective 2026-08-09   │
                                  └───────────────────────────────┘

  ════════════════════════════════════════════════════════════════════════════════

  SUNSCREEN ORDER TIMELINE (M020) — A VERSION-CONTROL LESSON

  ┌──────────────────────────────────────────────────────────────────────────────┐
  │  OTC000006   effective 2021-09-24   carries forward part 352 / 201.327       │
  │                                    requirements → CURRENT BASE ORDER         │
  ├──────────────────────────────────────────────────────────────────────────────┤
  │  OTC000008   proposed              labeling, dosage forms, max SPF changes   │
  │                                    → PENDING; not a condition you can rely on│
  ├──────────────────────────────────────────────────────────────────────────────┤
  │  OTC000039   final 2026-06-10      adds bemotrizinol ≤ 6%                   │
  │              effective 2026-08-09  → ENFORCEABLE from effective date forward │
  ├──────────────────────────────────────────────────────────────────────────────┤
  │  OTC000008-1 issued 2026-09-11*    removes PABA and trolamine salicylate     │
  │              effective 2027-09-11  → FUTURE STATE; date-dependent evaluation │
  │              (* per order PDF;     PABA product conforming before that date, │
  │              FDA Q&A page shows    non-conforming on/after)                  │
  │              2026-09-10 — record   → record BOTH dates; use PDF as operative │
  │              both; flag discrepancy)                                          │
  └──────────────────────────────────────────────────────────────────────────────┘

  OMOR COST INPUT (classify before you spend)
  ─────────────────────────────────────────────
  Tier 1 OMOR (FY2027):   $614,608
  Tier 2 OMOR (FY2027):   $122,921
  NDA 505(b)(2):           $X (counsel estimate)

  → If the formula cannot conform without a new order, the memo must state
    'not manufacturable as OTC monograph without a new order or application'
    and hand off the economics question to program leadership.

  APPLICABILITY CLASSES USED IN EVERY NODE
  ──────────────────────────────────────────
  STATUTE              21 USC text (hard law)
  REGULATION           21 CFR text (binding rule)
  MONOGRAPH-CONDITION  final / deemed final order text (binding)
  PENDING-ORDER        proposed order (not yet binding)
  GUIDANCE/ADVISORY    FDA guidance (non-binding)
  INTERNAL-POLICY      this plant's SOP

  CONFIDENCE TAGS
  ───────────────
  verified-primary      read from operative order/statute PDF directly
  verified-secondary    read from a reliable secondary source; primary not checked
  unverified            not yet confirmed; blocks 'conforming' output

The complete §505G order lifecycle showing how pre-CARES monographs became deemed final orders, how new conditions proceed through proposed → final order states, and why only final (or deemed final) orders constitute enforceable conditions; illustrated with the actual M020 sunscreen order timeline.

---

Diagram 4: Drug vs. Cosmetic vs. Hybrid — Intended-Use Classification and Consequences

╔══════════════════════════════════════════════════════════════════════════════════════╗
║      DRUG vs COSMETIC vs HYBRID — 21 USC 321(g)(1) and 321(i)                       ║
╚══════════════════════════════════════════════════════════════════════════════════════╝

  WHAT DETERMINES CLASSIFICATION?  →  INTENDED USE
  ─────────────────────────────────────────────────
  Evidence of intended use is gathered from ALL of these simultaneously:

  ┌───────────────┐  ┌───────────────┐  ┌───────────────┐  ┌───────────────────────┐
  │  Label text   │  │  Advertising  │  │  Websites     │  │  Social media /        │
  │  (front panel,│  │  (print, TV,  │  │  (brand and   │  │  influencer claims     │
  │  Drug Facts,  │  │   digital)    │  │   third-party)│  │  on company channels   │
  │   back panel) │  └───────────────┘  └───────────────┘  └───────────────────────┘
  └───────────────┘
                     ┌────────────────────────────────────────────┐
                     │  + INGREDIENT with well-known drug use     │
                     │    (e.g., fluoride in toothpaste, HC)      │
                     │    can trigger drug status WITHOUT a claim  │
                     └────────────────────────────────────────────┘

  ════════════════════════════════════════════════════════════════════════════════

  CLAIM TAXONOMY — classify every phrase on every surface

  ┌──────────────────────────────┬──────────────────────────────────────────────┐
  │  CLAIM TYPE                  │  EXAMPLES                                    │
  ├──────────────────────────────┼──────────────────────────────────────────────┤
  │  COSMETIC (appearance,       │  'moisturizes', 'smooths', 'evens skin tone' │
  │  beautifying, cleansing)     │  'reduces the appearance of fine lines'      │
  │  → cosmetic only; no drug    │  'softens skin', 'brightens complexion'      │
  │    status from this alone    │                                              │
  ├──────────────────────────────┼──────────────────────────────────────────────┤
  │  STRUCTURE/FUNCTION          │  'stimulates collagen production'            │
  │  (affects body structure     │  'repairs skin barrier', 'boosts cell        │
  │   or function)               │  renewal', 'rebuilds elastin'               │
  │  → DRUG status triggered     │  'promotes skin regeneration'               │
  ├──────────────────────────────┼──────────────────────────────────────────────┤
  │  DISEASE / THERAPEUTIC       │  'treats eczema', 'prevents infection'       │
  │  (treat, prevent, cure,      │  'relieves pain', 'kills bacteria'          │
  │   mitigate disease)          │  'clears acne', 'antifungal'                │
  │  → DRUG status triggered     │  'reduces inflammation'                     │
  └──────────────────────────────┴──────────────────────────────────────────────┘

  ════════════════════════════════════════════════════════════════════════════════

  THREE OUTCOME CATEGORIES

        ┌───────────────────────────────────────────────────────────────────┐
        │                    PURE COSMETIC                                  │
        │  Only cosmetic claims; no well-known drug ingredient             │
        │                                                                   │
        │  Obligations (flag to PDDM914):                                  │
        │  · MoCRA registration + listing  (21 USC 364c)                   │
        │  · Serious AE reporting  (21 USC 364a, 15 business days)         │
        │  · Small-business exemption threshold  (21 USC 364h)             │
        │  · Florida cosmetic manufacturer permit  (§499.01(2)(p))         │
        │  · Cosmetic GMP rule pending  (NPRM listed 11/2027)              │
        │  · Drug-facility exemption (364i) does NOT cover pure cosmetics  │
        │    made in a drug facility                                        │
        └───────────────────────────────────────────────────────────────────┘

        ┌───────────────────────────────────────────────────────────────────┐
        │                 DRUG + COSMETIC (HYBRID)                          │
        │  Both drug and cosmetic claims present simultaneously             │
        │  Example: moisturizer with SPF claim; tinted sunscreen           │
        │                                                                   │
        │  Obligations:                                                     │
        │  · BOTH drug-facility and MoCRA obligations apply               │
        │  · Drug Facts panel (21 CFR 201.66) for sunscreen actives        │
        │  · Cosmetic ingredient declaration also required                  │
        │  · ZnO example: M016 protectant vs M020 sunscreen — the         │
        │    CLAIM decides which monograph applies                          │
        └───────────────────────────────────────────────────────────────────┘

        ┌───────────────────────────────────────────────────────────────────┐
        │                      PURE DRUG                                    │
        │  Only drug claims; proceed to Route A / B determination           │
        └───────────────────────────────────────────────────────────────────┘

  ════════════════════════════════════════════════════════════════════════════════

  PEPTIDE 'ANTI-AGING' CREAM — WORKED EXAMPLE

  ┌─────────────────────────────────────────────────────────────────────────────┐
  │  CLAIM SURFACE AUDIT                                                        │
  │                                                                             │
  │  Claim: 'stimulates collagen synthesis'  → STRUCTURE/FUNCTION → DRUG      │
  │  Claim: 'repairs damaged skin'           → STRUCTURE/FUNCTION → DRUG      │
  │  Claim: 'smooths wrinkles'               → COSMETIC (appearance)           │
  │  Ingredient: GHK-Cu (known for wound-healing association)                  │
  │              → well-known therapeutic use → supports DRUG reading          │
  │                                                                             │
  │  OUTCOME: DRUG status triggered                                            │
  │                                                                             │
  │  ROUTE CHECK:                                                               │
  │  · 'Stimulates collagen' → no OTC monograph covers this indication        │
  │  · GHK-Cu: 503A Category 1 status does NOT create a manufacturer route    │
  │  · No approved NDA for this ingredient/claim combination                   │
  │                                                                             │
  │  CLASSIFICATION: UNAPPROVED NEW DRUG                                       │
  │  REMEDIATION: Delete/rephrase all structure/function claims → cosmetic;    │
  │               or file an NDA (no monograph route available)                │
  └─────────────────────────────────────────────────────────────────────────────┘

The drug/cosmetic/hybrid classification system showing how intended use is determined from all claim surfaces simultaneously, how the three claim types map to regulatory outcomes, and how the peptide anti-aging cream example is analyzed using this framework.

---

Diagram 5: Compounding vs. Manufacture — Why This Plant Is Always a Manufacturer

╔══════════════════════════════════════════════════════════════════════════════════════════╗
║         COMPOUNDING vs. MANUFACTURE — THE DECISIVE BOUNDARY FOR THIS OPERATION          ║
╚══════════════════════════════════════════════════════════════════════════════════════════╝

  THE CORE PRINCIPLE:
  21 CFR 207.1 defines 'manufacture' so broadly that compounding appears inside it.
  FL §499.003 mirrors this. FL §465.003 pharmacy compounding applies ONLY to
  licensed pharmacies — not to this facility. FAC 64B16-27.700 (amended 2026-08-03).

  ════════════════════════════════════════════════════════════════════════════════════════

  503A EXEMPTION — 21 USC 353a(a)                   503B EXEMPTION — 21 USC 353b(d)(4)
  ───────────────────────────────────               ──────────────────────────────────
  ALL THREE conditions required:                    Applies to:

  ┌──────────────────────────────────┐              ┌──────────────────────────────────┐
  │ 1. Valid Rx for an IDENTIFIED    │              │ · STERILE drugs only             │
  │    INDIVIDUAL PATIENT            │              │ · Registered 'outsourcing        │
  │    (not 'office use';            │              │   facility'                      │
  │     not a batch for stock)       │              │ · Must comply with cGMP          │
  ├──────────────────────────────────┤              │                                  │
  │ 2. Compounded by a LICENSED      │              │  ← NOT APPLICABLE to:            │
  │    PHARMACIST or PHYSICIAN       │              │     nonsterile creams,           │
  │    (this facility's chemist      │              │     ointments, lotions, gels     │
  │     does not qualify)            │              │                                  │
  ├──────────────────────────────────┤              │  503B bulks list (DPCP, SADBE,   │
  │ 3. Bulk substance conditions:    │              │  glycolic acid ≤70%, TCA,        │
  │    · USP/NF monograph, OR        │              │  topical only) is context only — │
  │    · Approved-drug component, OR │              │  not a manufacture route for     │
  │    · 503A bulks list             │              │  this plant                      │
  │    · CoA required                │              └──────────────────────────────────┘
  │    · §510-registered source      │
  └──────────────────────────────────┘

  ════════════════════════════════════════════════════════════════════════════════════════

  THIS PLANT'S LEGAL STATUS — ALWAYS A MANUFACTURER

  ┌─────────────────────────────────────────────────────────────────────────────────────┐
  │                                                                                     │
  │   Any batch of cream/ointment/lotion/gel made in this facility for supply           │
  │   beyond an individual named patient's valid prescription                           │
  │                                                                                     │
  │                              IS MANUFACTURE                                         │
  │                                                                                     │
  │   Governing standards:   21 CFR 210 / 211  (full cGMP — no exemption)             │
  │   NOT governing:         USP <795> (nonsterile compounding)                        │
  │   NOT governing:         USP <1163> (quality attributes, CNSPs)                   │
  │   NOT governing:         FDA insanitary-conditions compounding guidance            │
  │   NOT governing:         aw-based BUDs from USP <795>                             │
  │                                                                                     │
  └─────────────────────────────────────────────────────────────────────────────────────┘

  ════════════════════════════════════════════════════════════════════════════════════════

  EDGE CASES — ALL RESOLVED AS MANUFACTURE

  ┌─────────────────────────────────────────────────────────────────┬──────────────────┐
  │  SCENARIO                                                       │  CLASSIFICATION  │
  ├─────────────────────────────────────────────────────────────────┼──────────────────┤
  │  Dermatologist requests patient-named jars from this plant      │  MANUFACTURE     │
  │  (no pharmacy license; no patient-specific Rx pathway here)     │                  │
  ├─────────────────────────────────────────────────────────────────┼──────────────────┤
  │  Dermatologist requests 'office use' supply (no individual Rx)  │  MANUFACTURE     │
  │  → not within 503A even for a licensed pharmacist               │                  │
  ├─────────────────────────────────────────────────────────────────┼──────────────────┤
  │  Small 'compounding-style' batch, e.g., 12 jars                 │  MANUFACTURE     │
  │  (batch size is irrelevant to the legal definition)             │                  │
  ├─────────────────────────────────────────────────────────────────┼──────────────────┤
  │  Physician authors the formula; claims 'medical-grade'          │  MANUFACTURE     │
  │  → physician authorship does not invoke 503A for this plant     │                  │
  ├─────────────────────────────────────────────────────────────────┼──────────────────┤
  │  Florida OTC-manufacturer permit bars Rx possession             │  Flag → PDDM914  │
  │  Mupirocin, silver sulfadiazine, non-M004 antibiotics           │  (Rx hard stop)  │
  └─────────────────────────────────────────────────────────────────┴──────────────────┘

  MEMO LANGUAGE (required when compounding framing is raised):
  ─────────────────────────────────────────────────────────────
  'This activity constitutes manufacture under 21 CFR 207.1 and FL §499.003.
   The 503A exemption (21 USC 353a) is inapplicable: [state which condition fails].
   The 503B exemption (21 USC 353b) is inapplicable: the product is nonsterile.
   All operations are governed by 21 CFR 210/211 in full. USP <795> does not apply.'

The legal boundary between compounding exemptions and manufacture, showing why neither 503A nor 503B applies to this plant's nonsterile topical operations, and resolving the most common edge cases that practitioners try to frame as compounding.

---

Key Takeaways

  1. Classification is the gate, not the formulation. Under PDDM901, no purchasing decision, method development, facility investment, or materials work begins on an unclassified specification. The route code — MONO / APP / COMPOUND / NO-GO — is the first output of every new product intake, and it drives all downstream obligation flags (PDDM902/914/923/924).
  2. There are exactly three legal routes for a topical OTC drug, and only Route A is the default for this plant. Route A is the §505G monograph route (21 USC 355h + 21 CFR 330.1). Route B is an approved application (NDA 505(b)(1)/(b)(2), ANDA, or switch NDA). Route C is compounding (503A or 503B). This plant is a manufacturer under 21 CFR 207.1 and operates only Route A by default; Routes B and C require either a regulatory application or a licensed pharmacy, neither of which this facility currently holds.
  3. The CARES Act (Pub. L. 116-136, 2020-03-27) converted final monographs and Category I tentative final monographs into deemed final orders by operation of law, under 21 USC 355h(b), without any additional FDA action. For example, M016 became Final Administrative Order OTC000005 automatically. New or amended conditions now require a proposed order → comment period → final order cycle, which can take years. A proposed order (e.g., the sunscreen OTC000008 on labeling, dosage forms, and maximum SPF) is not yet enforceable and cannot be relied upon as a manufacturing condition.
  4. A monograph concentration window is a legal-category limit, not a dose recommendation. A formula at exactly the ceiling is legally no different from one at the floor — both are within the category. A formula even 0.01% above the ceiling is an unapproved new drug requiring an NDA or ANDA. HC 2% cream illustrates this precisely: the M017 ceiling is 1%, so HC 2% is non-conforming and requires an approved application regardless of its therapeutic familiarity.
  5. Dosage form is a condition, not a description. ZnO 30% in a cream fails the M016 monograph (cream ceiling = 25%) while ZnO 30% in an ointment conforms (ointment allows >25%–40%). Lidocaine 4% in a cream conforms to M017, but lidocaine 4% in a patch does not — M017 excludes patch, plaster, and poultice forms entirely. The dosage-form check runs independently of the concentration check; passing one does not imply the other passes.
  6. Salt form is part of the active ingredient identity condition. "Lidocaine" and "lidocaine HCl" are listed as distinct entries in M017; "miconazole" and "miconazole nitrate" are distinct entries in M005. A formula using the free base when only the salt form is listed — or vice versa — fails Dimension 1 of the conditions check before even reaching the concentration window. This is not pedantry: the salt form affects the molecular weight, the counterion load, and the regulatory history of the substance.
  7. The combination rules apply only to claimed actives; excipients are transparent to the check. M016 §.20(c) prohibits a labeled skin-protectant active being combined with hydrocortisone as a co-labeled active. But petrolatum as an unlabeled excipient in an HC 1% base is not caught by §.20(c) — the rule only fires when the protectant is claimed. This distinction is operationally critical: it determines whether a multi-ingredient formula needs a combination-rule citation or not, and mislabeling the check in either direction creates either a false pass or an unnecessary reformulation.
  8. Intended use is determined from all claim surfaces simultaneously, not just the label. Under 21 USC 321(g)(1), a product becomes a drug if its labeling, advertising, website, social media, or even the well-known therapeutic use of its ingredients indicates a drug purpose. The peptide 'anti-aging' cream with claims like 'stimulates collagen synthesis' or 'repairs skin barrier' is a drug regardless of how the label is written, because those phrases indicate a structure/function effect on the body. GHK-Cu's 503A Category 1 status does not create a manufacturer route — it applies only to licensed compounding pharmacies.
  9. Hydroquinone at any concentration is an absolute hard stop for OTC manufacture. FDA's effective date for this position is 2020-09-23. There is no legally marketed OTC HQ skin-lightening product. Tri-Luma (hydroquinone 4% + fluocinolone + tretinoin) is the only approved HQ product, and it is Rx-only. FDA sent 12 warning letters on 2022-04-19. The memo must state this plainly; there is no concentration or formulation variant that circumvents this hard stop.
  10. Date-dependent classification is a first-class feature, not an edge case. OTC000008-1 removes PABA and trolamine salicylate from the sunscreen monograph with an effective date of 2027-09-11. A PABA sunscreen product with a distribution date before that date classifies as conforming (subject to all other conditions); the same product intended for distribution on or after that date classifies as non-conforming. The classification engine must evaluate against the intended distribution and expiry dates, not the intake date. When an order is posted but not yet effective, the conditions record must record both the posting date and the effective date and flag the future-state transition.
  11. 21 CFR 330.1(a)–(b) requires cGMP compliance (Parts 210/211) and registration/listing (Part 207) as conditions of the monograph exemption, but the classification gate does not resolve these — it only emits flags. A formula that passes all five monograph-conditions dimensions is GRASE and not misbranded only if those facility conditions are also met. The classification memo emits facility-obligation flags to PDDM914; it does not certify facility compliance. This division of responsibility is architecturally deliberate: conflating the formula check with the facility check creates a false sense of readiness.
  12. Neither 503A nor 503B applies to this plant's operations under any scenario, including small batches, physician-authored formulas, or dermatologist office-use requests. 503A requires a valid prescription for an identified individual patient, compounding by a licensed pharmacist or physician — conditions this manufacturing facility cannot meet. 503B covers only sterile drugs in registered outsourcing facilities, not nonsterile topicals. Batch size is irrelevant to the legal definition. When a dermatologist or sales contact frames a request as 'compounding,' the classification memo must explicitly reject that framing using the language of 21 USC 353a/353b and 21 CFR 207.1.
  13. Switch-NDA actives (adapalene, terbinafine, butenafine, diclofenac, minoxidil) are OTC drugs but are not monograph drugs — a generic version requires an ANDA, not a monograph compliance memo. The absence of these actives from any final order is the dispositive fact. Ketoconazole, terbinafine, butenafine, and ciclopirox are absent from M005 (which covers only clotrimazole 1%, miconazole nitrate 2%, tolnaftate 1%, undecylenates 10–25%, and a few others); a cream containing any of those non-listed actives routes directly to Route B. The switch-point triage flags (e.g., HC 1%, lidocaine 4%, BPO 10%) are non-dispositive shortcuts — they signal that a close review is needed, not that the formula passes or fails.
  14. The source hierarchy for monograph conditions is: operative order/monograph PDF and eCFR/US Code text > FDA Q&A and summary pages > secondary copies. The OTC Monographs@FDA portal is JavaScript-rendered and cannot be fully scraped; the individual monograph and order PDFs are the operative documents. When a discrepancy exists between an order PDF date (OTC000008-1: 2026-09-11) and the FDA Q&A page (2026-09-10), record both, use the operative PDF, and document the discrepancy. Any row in the conditions table older than the defined staleness interval must trigger a re-check before it can support a 'conforming' classification output.
  15. The confidence tag on every node in the classification path sets the confidence floor of the entire memo, and an unverified row blocks a 'conforming' output. The three tags are: verified-primary (read directly from the operative order or statute), verified-secondary (read from a reliable secondary source, primary not yet checked), and unverified (not yet confirmed). The memo's confidence floor equals the lowest tag on the decision path. An unverified node — even one that appears to support a passing conclusion — cannot produce a conforming classification. This is the machine-readable equivalent of the scientific principle that a chain of reasoning is only as strong as its weakest link.
---

References

  1. United States Congress, 'Coronavirus Aid, Relief, and Economic Security Act (CARES Act),' Pub. L. 116-136, signed 2020-03-27. Codified in part at 21 USC 355h (§505G of the Federal Food, Drug, and Cosmetic Act).
  2. United States Code, 'Federal Food, Drug, and Cosmetic Act §201(g)(1) and §201(i): Definitions of drug and cosmetic,' 21 USC 321(g)(1) and 321(i).
  3. United States Code, 'Federal Food, Drug, and Cosmetic Act §503A: Pharmacy compounding,' 21 USC 353a.
  4. United States Code, 'Federal Food, Drug, and Cosmetic Act §503B: Outsourcing facilities,' 21 USC 353b.
  5. United States Code, 'Federal Food, Drug, and Cosmetic Act §§760–761: Cosmetic safety and registration (MoCRA),' 21 USC 364–364j.
  6. Code of Federal Regulations, 'General conditions for general recognition as safe and effective and not misbranded,' 21 CFR 330.1.
  7. Code of Federal Regulations, 'Drug products containing certain active ingredients offered over-the-counter (OTC) for certain uses,' 21 CFR 310.545.
  8. Code of Federal Regulations, 'Definitions,' 21 CFR 207.1 (definitions including manufacture and private-label distributor).
  9. Code of Federal Regulations, 'Format and content requirements for over-the-counter drug product labeling,' 21 CFR 201.66 (Drug Facts format).
  10. U.S. Food and Drug Administration, Center for Drug Evaluation and Research, 'OTC Monograph M003: First Aid Antiseptic.' Available via OTC Monographs @ FDA portal: https://www.accessdata.fda.gov/scripts/cder/omuf/
  11. U.S. Food and Drug Administration, Center for Drug Evaluation and Research, 'OTC Monograph M004: First Aid Antibiotic.' Available via OTC Monographs @ FDA portal.
  12. U.S. Food and Drug Administration, Center for Drug Evaluation and Research, 'OTC Monograph M005: Topical Antifungal.' Available via OTC Monographs @ FDA portal.
  13. U.S. Food and Drug Administration, Center for Drug Evaluation and Research, 'OTC Monograph M006: Topical Acne.' Available via OTC Monographs @ FDA portal.
  14. U.S. Food and Drug Administration, Center for Drug Evaluation and Research, 'OTC Monograph M016: Skin Protectant,' Final Administrative Order OTC000005. Available via OTC Monographs @ FDA portal.
  15. U.S. Food and Drug Administration, Center for Drug Evaluation and Research, 'OTC Monograph M017: External Analgesic (Topical).' Available via OTC Monographs @ FDA portal.
  16. U.S. Food and Drug Administration, Center for Drug Evaluation and Research, 'OTC Monograph M020: Sunscreen,' Final Administrative Order OTC000006, effective 2021-09-24. Available via OTC Monographs @ FDA portal.
  17. U.S. Food and Drug Administration, Center for Drug Evaluation and Research, 'Sunscreen Monograph: Final Administrative Order OTC000039,' issued 2026-06-10, adding bemotrizinol ≤6%, text effective 2026-08-09. Available via OTC Monographs @ FDA portal.
  18. U.S. Food and Drug Administration, Center for Drug Evaluation and Research, 'Sunscreen Monograph: Final Administrative Order OTC000008-1,' issued 2026-09-11 per order PDF (2026-09-10 per FDA Q&A page — discrepancy noted), removing PABA and trolamine salicylate, effective 2027-09-11. Available via OTC Monographs @ FDA portal.
  19. U.S. Food and Drug Administration, Center for Drug Evaluation and Research, 'OTC Monograph M032: Dandruff, Seborrheic Dermatitis, Psoriasis.' Available via OTC Monographs @ FDA portal.
  20. U.S. Food and Drug Administration, 'Is It a Cosmetic, a Drug, or Both? (Or Is It Soap?),' FDA Consumer Information. Available at: https://www.fda.gov/cosmetics/cosmetics-laws-regulations/it-cosmetic-drug-or-both-or-it-soap
  21. U.S. Food and Drug Administration, 'FDA works to protect consumers from potentially harmful OTC skin lightening products (hydroquinone),' FDA Drug Safety Communication, effective 2020-09-23. FDA issued 12 warning letters 2022-04-19.
  22. U.S. Food and Drug Administration, 'Questions and Answers: FDA's regulatory actions on OTC sunscreen products.' Available at FDA website (verify current URL).
  23. Florida Statutes, 'Florida Drug and Cosmetic Act,' Chapter 499, §§499.003 (definitions), 499.01(2)(a),(n),(p) (permits), 499.015 (registration).
  24. Florida Statutes, 'Pharmacy compounding,' §465.003 (definitions applicable to licensed pharmacies only).
  25. Florida Administrative Code, 'Compounding for Office Use,' FAC 64B16-27.700, as amended effective 2026-08-03.
  26. Regulatory Affairs Professionals Society (RAPS), 'Fundamentals of US Regulatory Affairs,' current edition (verify edition year and publisher). RAPS, Rockville, MD.
  27. Adams, D.G.; Cooper, R.M.; Hahn, M.J.; Kahan, J.S. (eds.), 'Food and Drug Law and Regulation,' 3rd ed. Food and Drug Law Institute (FDLI), Washington, DC, 2015.
  28. Hutt, P.B.; Merrill, R.A.; Grossman, L.A., 'Food and Drug Law: Cases and Materials,' 5th ed. (verify edition year). Foundation Press.
  29. Buhse, L.; Kolinski, R.; Westenberger, B.; et al., 'Topical drug classification,' International Journal of Pharmaceutics, 2005. DOI: 10.1016/j.ijpharm.2005.01.032
  30. Salzmann, S. et al., 'Compounded preparations in dermatology – analysis of prescribing habits in everyday clinical practice in Germany,' Journal der Deutschen Dermatologischen Gesellschaft, 2020. DOI: 10.1111/ddg.14071
  31. Kiseļova, O. et al., 'Analysis of Extemporaneous Prescriptions Prescribed by Dermatovenerologists in Latvia and Comparison with Standardized Compounded Preparation Monographs of Germany and USA,' Medicina (Kaunas), 2020. DOI: 10.3390/medicina56010029
  32. Campbell, E.H.; Elston, D.M.; Straughan, C.L.; Antonovich, D.D., 'Regulations, liability, safety, and economics related to compounding,' Journal of the American Academy of Dermatology, 2020. DOI: 10.1016/j.jaad.2019.11.061
  33. Ly, S. et al., 'Dermatologists' use of compounding pharmacies and knowledge of associated regulations,' International Journal of Dermatology, 2023. DOI: 10.1111/ijd.16520